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Abstract 
Medulloblastoma (MB) is a highly malignant brain tumor that occurs primarily in 
children. Although surgery, radiation and high-dose chemotherapy have led to increased 
survival, many MB patients still die from their disease, and patients who survive suffer 
severe long-term side effects as a consequence of treatment. Thus, more effective and 
less toxic therapies for MB are critically important. Identifying new treatments will require 
an understanding of early stages of tumor development, as well as the pathways that are 
critical for the growth and maintenance of established tumors. In these studies, we 
explore the roles of WNT signaling in cerebellar development and tumor initiation and of 
Survivin in the proliferation and survival of tumors. 
The WNT pathway plays multiple roles in neural development, is crucial for 
establishment of the embryonic cerebellum, and is highly expressed in a subset of MBs. 
However, the cell types within the cerebellum that are responsive to WNT signaling 
remain unknown. We show that expression of activated β-catenin promotes proliferation 
of cerebellar neural stem cells (NSCs), but interferes with their capacity for self-renewal 
and differentiation. These studies suggest that the WNT pathway is a potent regulator of 
cerebellar stem cell growth and differentiation and that NSCs may represent a cell of 
origin for WNT-associated MB.  
In addition to understanding early stages of transformation, identifying 
vulnerabilities of established tumors will be critical for development of targeted therapies. 
We have focused our studies on the role of the inhibitor of apoptosis protein (IAP) 
Survivin in Sonic hedgehog (SHH)-driven MB.  Here we show first that Survivin is 
overexpressed in murine SHH-driven MB. Using genetic and pharmacological 
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approaches, we demonstrate that inhibition of Survivin impairs proliferation and survival 
of both murine and human MB cells. These studies highlight the importance of Survivin 
in SHH-driven MB, and suggest that it may represent a novel therapeutic target in 
patients with this disease.  
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1. Introduction 
1.1 Medulloblastoma 
Medulloblastoma (MB) is an embryonal tumor of the cerebellum and is the most 
common malignant brain tumor that occurs in children1. Although it presents primarily in 
infants and children, with peak incidence between 3-7 years of age, MB also accounts 
for 1-2% of adult brain tumors2.  MBs were originally treated as a single disease, but 
recognition of the heterogeneity of this disease in terms of histology and pathology, as 
well as response to treatment, led to stratification into defined histological subtypes. 
World Health Organization (WHO) designations for the disease have developed over the 
years as our understanding of the disease has increased and as of 2007, the WHO 
recognizes five histological subtypes: classic, anaplastic, large cell, 
desmoplastic/nodular, and medulloblastoma with extensive nodularity (MBEN)3, although 
the majority of studies have combined large cell/anaplastic phenotypes. Most MBs 
display differentiation primarily along the neuronal lineage, with minimal display of glial 
markers4. Classical MBs, which compromise ~65% of cases, consist of sheets of 
undifferentiated small, round cells with characteristic high cytoplasmic-to-nuclear ratio. 
Anaplastic/large cell tumors are more aggressive tumors, characterized by pleomorphic 
cells and high mitotic indexes compared to other types of MB. Desmoplastic/nodular 
MBs contain areas of more differentiated, non-proliferative cells (nodules) that are 
reticulin negative surrounded by areas of desmoplasia. MBEN tumors display larger and 
more frequent nodules than desmoplastic/nodular tumors4. Prognosis for MBEN and 
desmoplastic/nodular patients is more favorable than for those with classical MB5, while 
large cell/anaplastic tumors are associated with display the worst prognosis6. 
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Early studies of familial inherited mutations that predisposed to MB development 
provided the first insights into the different molecular drivers of the disease. Germline 
mutations in PTCH1,a negative regulator of the sonic hedgehog (SHH) pathway, are 
associated with Gorlin syndrome, which is characterized by a high occurrence of 
spontaneous MBs 7,8. Similarly, patients with germline mutations in the SHH pathway 
component SUFU are predisposed to development of MB9. These cases highlight the 
importance of SHH signaling for driving MB in patients.  Turcot’s syndrome, a disorder 
characterized by increased incidence of colon cancer and brain tumors (often 
medulloblastomas) results from germline mutations in the adenomatous polyposis coli 
(APC) gene, a negative regulator of canonical WNT signaling10. In addition, 15-20% of 
sporadic medulloblastomas harbor activating mutations in β- catenin or inactivating 
mutations in APC11-14. These and other studies have led to the understanding that many 
the pathways that are dysregulated in MB (such as SHH and WNT) are critical for 
normal cerebellar development. 
In the past ~6 years, there is has been a huge outpouring of data regarding the 
molecular alterations that occur in MBs. Consensus from numerous genetic and 
genomic studies has solidified the classification of MBs into four main subtypes-SHH, 
WNT, Group 3, and Group 4- with the possibility of further subgroups within these 
types15. Importantly, these molecular subgroups of MB display distinct genetic and 
molecular alterations, clinical features, and prognosis15-19. The best studied of these are 
the SHH subtype, so designated because tumors are associated with mutations or 
activation of the SHH signaling pathway, which represent ~28% of human MBs. 
Interestingly, these tumors have a bimodal age distribution, with the majority occurring  
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in infants or  in teenagers and adults, but few in children16,19. SHH driven tumors 
commonly display classic or desmoplastic histology, do not frequently metastasize, and 
are associated with intermediate survival15. The WNT subtype is least frequent subtype, 
accounting for about 10-11% of MB cases16,17. These tumors have the most favorable 
prognosis, with recent estimates that >90%of patients survive their disease15, although 
they still suffer from debilitating side effects of the therapies. In fact, these patients are 
likely over-treated and current clinical trials are being developed to address scaling back 
radiation for these patients to minimize toxicities15. These tumors typically occur in 
children above the age of three, commonly display classical histology, and rarely 
metastasize16,17. These two subtypes will be the focus of the studies presented in 
Chapters 2 and 3. Group 3 and Group 4 MB are less well characterized and display 
worse prognosis than the other two subtypes. These tumors are more metastatic and 
often display large cell/anaplastic phenotypes16,19. 
The identification of medulloblastoma subgroups has not yet influenced clinical 
practice to any large degree. Patients are still designated as high or low risk based on 
age at diagnosis, residual tumor size, and presence of leptomenigial metastasis alone17. 
Genomic stratification of patients and molecularly targeted therapies are just starting to 
be implemented in clinical trials for SHH driven MB20,21,  but are not yet common 
practice. The current standard of care for MB (independent of subtype) is surgical 
resection, followed by cranio-spinal radiation (for children above 3 years of age) and 
high dose chemotherapy. For patients with non-disseminated disease, upwards of 80% 
are expected to survive beyond 5 years post treatment with the current aggressive 
treatment regimen22. Unfortunately, these treatments are associated with long term 
consequences affecting quality of life, especially in young children. Severe cognitive 
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deficits, endocrine disorders, and increased incidence of other cancers later in life occur 
in many MB survivors23. Moreover, still almost a third of the patients remains incurable 
and will eventually succumb to the disease. Therefore, to minimize detrimental aspects 
of treatment and to continue improving overall cure rates in patients, more targeted, 
specific therapies are needed. These therapies may need to be subtype specific, and 
identification of appropriate strategies will require a more in depth understanding of the 
early steps of neoplastic transformation and identification of pathways that tumors rely 
on for growth and maintenance. 
1.2 Cell of origin 
Cancer develops from progeny of normal cells that acquire somatic mutations 
that allow them to survive and proliferate unchecked. The “cell of origin” is a term that 
describes the normal cells that acquire these initial driver mutations and subsequently 
give rise to tumors. Understanding these normal-tumor cell relationships is crucial for 
understanding cancer progression and identifying vulnerabilities for novel therapies. 
Different populations of cells are responsive to particular signaling pathways during 
normal development, which orchestrate their growth, proliferation, migration, and 
differentiation. These pathways may be co-opted in cancer, causing transformation in 
susceptible cell types, which can provide insights into early drivers of the disease. There 
is clearly a relationship between normal cerebellar development and drivers of MB 
tumorigenesis, as two of the major subtypes are characterized by activation of cerebellar 
developmental pathways (SHH and WNT)15. Importantly, these subgroups maintain 
distinct signatures, biological behaviors (where tumors are located, how they develop), 
and clinical prognosis16,19,24, supporting the notion that it is important to understand the 
 5 
underlying basis of these differences. The distinct subtypes of medulloblastoma are 
likely due at least in part to the different cellular contexts in which these tumors arise, 
and these differences may be responsible for their differential responses to therapy25.  
Importantly, identification of the cell of origin for the subtypes of MB allows for the 
development of mouse models that phenocopy the human disease. These models 
provide insights into the early stages of transformation and can be used to identify 
critical genetic /epigenetic alterations that occur during tumor development and 
progression. This will allow for identification of particular vulnerabilities of each subtype 
of the disease that can be targeted for therapies. These models also provide an 
important preclinical platform for testing of novel therapeutics. It is therefore of great 
interest for both researchers and clinicians to identify and characterize the cell of origin 
for each of the MB subtypes.  
In order to explore the cell of origin, we first need to examine the populations of 
normal cells in the cerebellum that could potentially give rise to tumors and the signals 
that regulate their development. 
1.2.1 Normal Cells of the cerebellum  
There are two main germinal zones in the developing cerebellum that produce 
the majority of cell types: the ventricular zone (VZ) and the rhombic lip. Most cells types 
in the cerebellum are derived from the VZ; it contains multipotent stem cells that give 
rise to Purkinje, stellate, basket and golgi interneurons26,27. Granule neuron precursors 
(GNPs), in contrast, are derived from the rhombic lip28, and give rise to a single cell type, 
the granule neuron27. These germinal zones for stem cells and granule neuron 
precursors are thought to be the origins for different subtypes of MB. 
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The neuroepithelial VZ is located in the roof of the fourth ventricle and consists 
mainly of multipotent cerebellar neural stem cells (NSCs)27,29. These cells proliferate in 
the VZ during embryogenesis, then migrate toward the surface of the cerebellum and 
differentiate to form the majority of glia and neurons. The first cell type they give rise to is 
the nuclear neurons (E10-12) which migrate into the deep layers of the cerebellum. The 
next major cell type, the Purkinje cells, are born and exit the VZ from E11-13, migrate 
radially into the cerebellar anlage, and eventually form a single cell layer suspended 
below the molecular layer and above the future internal granule layer. Around the time 
Purkinje cells stop proliferating, a small number of stem cells from the VZ migrate to the 
rhombic lip, turn on the transcription factor Atoh1/Math1 (committing to the granule 
lineage) and generate GNPs. As development continues, the VZ diminishes and gives 
rise to golgi neurons, and stellate and basket cells that populate the molecular layer 
postnatally30. The VZ eventually disappears during postnatal development. In addition to 
these stem cells, there are a small number of stem cells that reside in the white matter of 
the postnatal cerebellum31. These cells are characterized by expression of the cell 
surface marker Prominin1/CD133 and lack of glial and neuronal lineage markers. It is 
unclear what their contribution to developing cerebellum is, although they are capable of 
self-renewal and differentiation into neurons, oligodendrocytes, and glia in vitro and 
following transplantation.   
GNPs are lineage restricted progenitors that are born in the rhombic lip, 
proliferate, and begin to migrate tangentially across the surface of the cerebellum around 
E13 to form the external granule layer (EGL) (below the meninges and above the 
molecular layer)27,29,32. These cells are characterized by expression of Math1 and Zic1, 
among other factors. Cells in the outer EGL proliferate extensively in response to SHH 
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ligand produced by neighboring Purkinje cells33 and form a thick layer, peaking in size at 
postnatal day 7. As cells migrate from the outer to inner EGL, they start to lose Math1 
expression and exit the cell cycle. Inner EGL cells then migrate along Bergmann glial 
fibers through the molecular layer and past the Purkinje cell layer, and differentiate into 
mature granule neurons, forming the internal granule layer. By P21, all GNPs have 
migrated inward, leaving the surface of the cerebellum free of cells. In humans, the 
GNPs appear in the EGL by week 27 and the differentiation/migration process that 
clears the surface of the cerebellum continues through the first year of life29. A very 
recent study has identified another small population of EGL resident cells that are 
distinct from GNPs and also give rise to granule neurons34. These cells are 
characterized by Nestin expression, are relatively quiescent, and do not proliferate in 
response to SHH in vivo.  
1.2.2 Signals that regulate cerebellar development 
Early stages of development of the cerebellar primordium are orchestrated by 
signals from the isthmus organizing center32. The isthmus organizer (IsO) region occurs 
in the neural tube at the boundary between what will be the midbrain and hindbrain, and 
importantly defines the anterior limit of the cerebellum through expression of FGF8. The 
position of the IsO is dependent on the reciprocal repression of two key molecules, Otx2 
and Gbx1, which are expressed in the mid- and hindbrain respectively35. Mistargeting 
experiments have highlighted the importance of each for modulating the positioning of 
the IsO and establishment of a sharp boundary36,37. The IsO, in turn, expresses and 
secretes key regulators of cerebellar development such as FGF8, WNT1, Engrailed 1 
and 2, and Pax 2 and 538, all of which feedback on each other to ensure correct 
patterning of the cerebellum. Inactivation or deletion of each of these molecules in 
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animals causes large deletions or complete ablation of the cerebellum 39-41,32,42, 
suggesting that they represent important regulators of early cerebellar development. 
Additionally, expression of Hox2A has been implicated in defining the posterior boundary 
of the cerebellum, as mice without Hox2A develop much larger cerebella43. 
There are a myriad of factors that contribute to the highly coordinated migration, 
proliferation, and eventual mitotic exit and differentiation of GNPs. Signaling for the 
specification of granule cells in the rhombic lip is initiated by bone morphogenic proteins 
(TGFbeta family proteins), specifically BMP6, BMP7 and Gdf744 that are secreted from 
cells in the roof plate of the fourth ventricle44. These molecules stimulate Math1 
expression. Loss of Math1 (Math1-/- mice) causes complete abrogation of the EGL and 
loss of granule neurons in the cerebellum45, suggesting that expression of this 
transcription factor is critical for GNP development. Once the cells reach the EGL, the 
predominant mitogenic signal for GNPs is SHH ligand, which is secreted by neighboring 
Purkinje cells33. Mutation or loss of Purkinje cells results in decreased proliferation and 
lower cell number of GNPs46,47, suggesting that signaling from these cells is crucial for 
normal GNP proliferation and expansion. Further, GNPs express the receptor for the 
SHH ligand, PTCH, and display increased expression of SHH target genes such as 
CyclinD2 and Nmyc, both of which are essential for GNP proliferation48,49. Activation of 
Notch signaling in GNPs (which express Notch2), suggests that this pathway can 
promote proliferation as well50. Other factors with known roles in GNP proliferation are 
Ru49/Zipro1, Zic1, and Zic251-53, all of which are expressed in the EGL. 
As cells move to the inner EGL, they begin to exit the cell cycle. Signals that control 
this decision to become postmitotic and to migrate and differentiate are not well 
understood.  Importantly, GNPs lose Math1 expression and increase NeuroD 
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expression, which is critical for GNP survival during differentiation and migration54. Loss 
of CXCR4, a receptor expressed in GNPs, or of its ligand CXCL12/SDF1-α, causes 
aberrant migration of a subset of GNPs into the IGL prior to differentiation, suggesting 
that signaling through CXCR4 is critical for maintenance of GNPs in the EGL55,56. 
Additionally, inner EGL GNPs upregulate Eng2, which promotes cell cycle exit and 
differentiation of GNPs57. It has been suggested that suppression of SHH signaling may 
contribute to the switch from proliferation to differentiation. Molecules such as bFGF and 
BMP2 (through SMAD5) are capable of antagonizing the proliferative response of GNPs 
to SHH and inducing differentiation58,59 , and have been suggested to play a role in this 
process. Notch2 is downregulated as GNPs exit the cell cycle and differentiate as well50, 
so loss of Notch signaling could contribute to the decreased proliferation and 
differentiation of these cells50. Additionally, p27/Kip1 (cyclin dependent kinase inhibitor) 
expression is limited to cells residing in the inner EGL60 and may contribute to the post-
mitotic state of these cells.  
In addition to proliferation, a low basal level of controlled apoptosis characterizes the 
EGL and contributes to controlling GNP cell number. Brain-derived neurotrophic factor 
(BDNF) and insulin-like growth factor (IGF1) signaling have been implicated as 
mediators of cell survival for this cell population61,62. Additionally, mutations in GIRK2, an 
inward rectifying K+ ion channel, have demonstrated the requirement of this protein for 
cell survival during differentiation (to counteract depolarization signaled by NMDA 
receptor activation during differentiation)63,64 .  
One of the major signaling pathways that has been identified for the terminal 
migration of GNPS is Netrin and its receptor Unc5H3, a pathway known to regulate 
neuronal migration and axonal projection in the CNS65. Unc5H3 is expressed on GNPs 
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and when mutated, cerebellar cells aberrantly migrate outside the normal boundaries of 
the cerebellum66. Similarly, Pax6 (Sey) mutant mice display abnormal migration, with 
post mitotic GNPs scattered through the EGL suggesting that Pax6 is another regulator 
of correct GNP migration67. This phenotype may be mediated in part by downregulation 
of Unc5H3 expression in the Pax6 mutant mice. Finally, interference with the interaction 
of GNPs with glial cells during migration by disrupting binding of Neuregulin to glial Erb4 
or blocking/mutating astrotactin  prevents normal migration as well29. 
Less is known about the signals that regulate the stem cell populations in the 
cerebellum. It is known that these cells can proliferate in response to bFGF in vitro31, in 
contrast to GNPs that differentiate in the presence of bFGF58. The Notch pathway is 
active in the VZ as well: deletion of Notch1 in early cerebellar cells (using Eng2-Cre) 
causes failure to differentiate into cells along the neural lineage in the cerebellum and 
increases apoptosis, pointing to a critical role of Notch signaling in determining fate of 
early cerebellar stem cells68. A recent study has demonstrated that expression of Ptf1a, 
a pancreatic transcription factor, in VZ cells is essential for their ability to produce 
Purkinje cells and interneurons69, and loss of Pfta1 allows some VZ derived cells to 
switch to an EGL progenitor cell fate70. So signaling through this pathway may be critical 
for VZ stem cell fate determination as well. The WNT pathway is clearly a critical 
regulator of early cerebellar development, as evidenced by complete ablation of the 
cerebellum in WNT1 knockout mice71. It is likely therefore that early stem cells may 
respond to WNT signaling. Additionally, WNT signaling is known to regulate progenitor 
and stem cell proliferation in the colon and CNS72,73. But its role in later stages of 
cerebellar development, and the identity of the cells in cerebellum that respond to WNT 
signaling, remain unclear. Deletion of β-catenin in Nestin+ cells prevents formation of the 
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cerebellar vermis without grossly affecting neuronal precursor diversification74. 
Additionally, activating and loss of function studies have suggested a role for WNT 
signaling in foliation of the cerebellum and in differentiation fate of cells born from the 
cerebellar ventricular zone75,76.  We will address the role of WNT signaling in cerebellar 
progenitors more specifically in Chapter 2.  
1.2.3 Potential Cells of origin for medulloblastoma subtypes  
The best studied subtype of medulloblastoma is the SHH subtype, and numerous 
mouse models of this subtype have been developed. Using a temporally controlled 
conditional deletion of the PTCH receptor, Yang et al have demonstrated that these 
tumors arise from the cerebellar granule cell lineage34. This was long suspected, as the 
SHH tumors share many characteristics with GNPs, including expression of the 
transcription factor Math1 and activation of SHH target genes. Further, pre-neoplastic 
lesions in Ptch mutant mice reside in the EGL and are capable of either differentiating 
into granule neurons or progressing to MB in a subset of mice77,78. Recent studies have 
demonstrated that other cells can also serve as cells of origin for this subtype, including 
stem cells79 and Nestin+ EGL cells34, although stem cells must acquire characteristics of 
the GNP lineage for these tumors to form79.  
In terms of the WNT-driven subtype of MB, work from the Gilbertson lab has 
demonstrated that these tumors can actually arise from cells outside the cerebellum24. 
BLBP+ cells from the floor of the fourth ventricle (dorsal brain stem progenitors) can be 
transformed by activation of β-catenin and loss of p53 into tumors in ~15% of mice . 
These tumors resemble human WNT tumors in terms of location in the brain and gene 
expression data. While these studies identify a putative cell of origin for WNT tumors, 
this may only represent a subset of WNT-driven tumors, namely those with p53 
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inactivation. It is possible that cells from within the cerebellum could also give rise to 
tumors. Our studies in chapter 2 examine the effects of activated WNT signaling in 
cerebellar progenitors and demonstrate that WNT signaling is mitogenic for cerebellar 
stem cells, but not for GNPs.  
The other two subgroups of medulloblastoma are not as well defined or studied. 
Currently no model exists for Group 4 tumors. In Group 3 tumors, one of the major 
alterations identified in this group is amplification or overexpression of the c-myc 
oncogene. Very recently, Dr. Yanxin Pei from our lab developed first model of this 
disease, an orthotopic allograft model derived from viral overexpression of c-myc and 
dominant negative p53 in postnatal cerebellar stem cells80. Importantly, this model 
recapitulates many features of the human disease. These studies came out concurrently 
with work by Kawauchi et al. showing that overexpression of c-myc in p53-null GNPs 
allows these cells to form Group 3-like tumors following transplantation81. Interestingly, 
both groups demonstrated that tumors generated from Atoh1+ GNPs lose their neuronal 
lineages markers and more closely resemble neural stem cells or induced pluripotent 
cells by expression profiling. This suggests that for Group 3 tumors, these oncogenes 
have to be activated either in a stem cell, or the progenitor cell has to acquire a stem-like 
phenotype (possibly through de-differentiation). So it is likely that stem cells represent 
the cell of origin for Group 3 tumors.   
These data demonstrate how critical developmental signaling pathways interact 
with particular stem and progenitor cell populations in order to form cellularly and 
molecularly distinct tumors.  
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1.3 Molecular targets in established tumors 
In addition to studying the early stages of tumorigenesis, examination of 
established tumors to identify pathways that tumors are dependent on for growth and 
survival will be critical for defining novel therapies. Genes that are highly expressed in 
tumors and mutations that commonly occur in these tumors provide insight into 
vulnerabilities that can be exploited for therapy.  
This strategy has been used to identify targeted therapies in numerous cancers. 
For example, it was discovered in 2002 that 40-50% of melanoma patients have 
activating mutations in BRAF 82 and as a consequence, exhibit constitutive MAPK 
pathway activation leading to uncontrolled cell proliferation and evasion of apoptosis83. 
This mutation was also associated with decreased survival in patients with metastastic 
melanoma84,85. The importance of BRAF for tumor growth led to the development of 
BRAF and MEK inhibitors to treat BRAF dependent melanomas, which both displayed 
positive responses in clinical trials86. Similarly, the recognition that a subset of breast 
cancers have amplified Her2 (a member of the epidermal growth factor receptor family of 
tyrosine kinases), and that expression predicts poor outcome in patients, led to testing of 
anti-Her2 antibodies (e.g. trastuzumab) and tyrosine kinase inhibitors (e.g. lapatinib) in 
this subset of patients87. These and other targeted therapies have shown great results in 
preclinical models and in trials86,87, although a common problem is development of 
resistance.   
This approach has recently begun to be utilized in MB as well. Genetic and 
genomic studies have identified mutations and genomic alterations that are specific for 
each subtype of MB and that could contribute to tumorigenesis. For example, c-myc 
amplification or overexpression occurs in Group 3 tumors and mutations in components 
 14 
of the WNT and SHH pathways occur specifically in their respective subgroups15. 
Recently, epigenetic modifiers have come up as a class of molecules that are commonly 
altered in MB and there are distinct mutations that occur specifically in Group 3 and 4 
(e.g KDM6A, EZH2, MLL2) or in WNT tumors (SMARC4, CREBBP)17,88,89.  Initial studies 
in our lab have shown that histone deacetylase (HDAC) inhibitors potently inhibit growth 
of murine and human Group 3 MB (Yanxin Pei et. al, in review).  In the SHH subtype of 
MB, a number of Smoothened (a mediator of SHH signaling) antagonists (GDC-049, 
LDE-225, IPI-926, PF5274857) have been developed to target this tumor90,91. These 
compounds have shown promising results in a number of SHH-driven mouse 
models90,92-94 and have been moved forward to clinical trials. In one patient with 
metastatic MB, treatment with GDC-049 caused a spectacular initial response with 
regression of all tumors20. Unfortunately, this response was not long-lived and tumors 
recurred. This rapid development of resistance is similar to what has been observed with 
other targeted therapies95,96.  So even in SHH-associated MB, additional therapeutics 
will be required to fully eradicate the disease. In Chapter 3, we identify Survivin as a 
gene of interest in SHH driven MB and investigate the potential of Survivin antagonists 
as novel therapeutic agents for treatment of MB.  
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2. WNT signaling increases proliferation and impairs 
differentiation of stem cells in the developing 
cerebellum 
2.1 Introduction 
WNT proteins play crucial roles in nervous system development97,98. Mutations in 
Wnt1 cause severe defects in the midbrain, hindbrain and developing spinal cord40,99,100 
and ablation of Wnt3a results in loss of the hippocampus101. Conversely, ectopic 
expression of β-catenin (a key activator of the canonical WNT signaling pathway) in 
neural precursors leads to expansion of the progenitor pool and enlargement of the 
forebrain and spinal cord102-104. In addition to its mitogenic effects in some parts of the 
CNS105,106 WNT signaling can also regulate cell fate determination107, differentiation108, 
axon growth109, synapse formation110,111 and myelination112. Thus, WNTs may have 
distinct effects on different cell types in the developing nervous system.  
Among the most widely studied functions of WNT signaling is in the 
establishment of the midbrain-hindbrain boundary that gives rise to the cerebellum40. 
However, the role of the pathway at later stages of cerebellar development is less well 
understood. At postnatal stages, Wnt7a is required for axonal branching by granule 
neurons and facilitates their formation of synapses with mossy fibers110,113 In addition, 
recent studies have shown that deletion of β- catenin in nestin-expressing progenitors 
results in premature neuronal differentiation and hypoplasia of the cerebellar vermis, 
suggesting that WNT signaling might regulate growth and differentiation in the 
embryonic and early postnatal cerebellum74. Perhaps the most striking evidence for the 
importance of WNT signaling in the cerebellum is the association between WNT 
pathway mutations and the cerebellar tumor medulloblastoma. Germline mutations in the 
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adenomatous polyposis coli (APC) gene, a negative regulator of canonical WNT 
signaling10, result in Turcot’s syndrome, a disorder characterized by increased incidence 
of colon cancer and brain tumors (often medulloblastomas). In addition, 15-20% of 
sporadic medulloblastomas harbor activating mutations in β- catenin or inactivating 
mutations in APC11-14. Recent studies suggest that WNT-associated medulloblastomas 
can arise from cells outside the cerebellum, in the dorsal hindbrain24, however, it 
remains possible that some of these tumors originate from progenitors within the 
cerebellum. Understanding the cells from which these tumors arise will be critical for 
identifying cooperating pathways and potential targets for therapy of this subtype. The 
ability of progenitors in the cerebellum to proliferate in response to WNT signaling 
remains poorly studied.  
The cerebellum contains two distinct germinal zones: the ventricular zone (VZ), 
which contains multipotent neural stem cells (NSCs) that give rise to the majority of 
cerebellar neurons and glia, and the external granule layer (EGL), which contains 
granule neuron precursors (GNPs) that give rise to a single cell type, the granule 
neuron27,29. To determine which of these cells is susceptible to the mitogenic effects of 
WNT signaling, we isolated NSCs and GNPs and tested their ability to proliferate 
following infection with β- catenin-encoding retroviruses. In addition, we used transgenic 
mice carrying a Cre-inducible allele of β-catenin to examine the effects of activating the 
WNT pathway in stem cells and progenitors in vivo. Our studies reveal that WNT 
signaling is not mitogenic for GNPs. By contrast, activation of the WNT pathway does 
promote proliferation of NSCs in the VZ, and these cells undergo expansion during 
embryonic development. However, this expansion is accompanied by loss of the ability 
to undergo self-renewal or differentiation and by failure to form most differentiated cell 
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types in the cerebellum. These studies suggest that WNT signaling plays an important 
role in regulating the growth and differentiation of stem cells in the developing 
cerebellum.  
These studies were performed in close collaboration with a post doc in the lab 
Dr. Yanxin Pei and data from each contributor will be indicated in figure legends (YP or 
SNB).  
2.2 Results 
2.2.1 Identification of cells in the developing cerebellum that proliferate in 
response to WNT signaling 
Although previous studies have shown that WNT signaling can promote the 
proliferation of progenitors in the cortex and spinal cord102,104, mitogenic effects of WNT 
signaling have not been described in the cerebellum. To determine whether cerebellar 
progenitors are responsive to canonical WNT signaling, we isolated cells from the 
embryonic cerebellum and tested their ability to proliferate following infection with 
retroviruses encoding activated β-catenin. Cells from embryonic day (E) 13.5 or E17.5 
were infected with control (GFP) or β-catenin-IRES-GFP viruses for 48 hours, pulsed 
with tritiated thymidine and assayed for thymidine incorporation. 
Whereas cells from E13.5 cerebellum exhibited a 2.5-fold increase in proliferation 
following infection with β-catenin-encoding cells viruses, cells from E17.5 showed no 
response (Fig. 1A). E13.5 cells also proliferated in response to soluble Wnt1 protein 
(Fig. 2). These studies suggested that WNT signaling is mitogenic for cells in the early 
embryonic cerebellum.  
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Figure 1:β-catenin increases the proliferation of a subpopulation of cells in 
the developing cerebellum. 
 (A)Cells from the cerebellum of E13.5 or E17.5 wild-type (WT) mice were infected 
with control (GFP only) or β-catenin-IRES-GFP retroviruses for 48 hours, pulsed 
with tritiated thymidine (3H-Td) and cultured overnight before being assayed for 
3H-Td incorporation. Data represent the mean (±s.e.m.) of triplicate samples. 
(B)GFP+ or GFP– cells were FACS sorted from cerebella of E14.5 hGFAP-GFP 
transgenic mice and infected with control (YFP only) or β-catenin-IRES-YFP 
retroviruses for 48 hours. There was no significant difference in infection rates of 
GFAP+ and GFAP– cells (45% and 40%, respectively). Cells were stained with Ki67 
antibodies and the percentage of Ki67+ cells was counted. Data represent the 
mean (±s.e.m.) percentage of Ki67+ cells in six fields **, P<0.01; ***, P<0.0001; 
Student’s t-test. YX.  
 
To determine which cells in the embryonic cerebellum proliferate in response to 
WNT signaling, we fractionated cells prior to infection with β -catenin-encoding viruses. 
The human GFAP (hGFAP) promoter is expressed in the VZ of the embryonic 
cerebellum, and FACS-sorted hGFAP-GFP+ cells can generate neurospheres and 
differentiate into neurons, astrocytes and oligodendrocytes79,114,115. Thus, the hGFAP 
promoter marks stem cells in the embryonic cerebellum. To determine whether these 
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cells can proliferate in response to WNT signaling, we FACS sorted GFP+ and GFP– 
cells from the cerebellum of hGFAP-GFP mice116 and infected them with retroviruses 
 
Figure 2:WNT1 protein increases proliferation of cells in the embryonic 
cerebellum. 
Cells were isolated from E13.5 or E17.5 WT cerebellum and cultured for 48 hours 
in serum-free medium containing no factors (control) or recombinant WNT1 
protein (black bars, 10 ng/ml; gray bars, 50 ng/ml; white bars, 200 ng/ml). Cells 
were pulsed with tritiated thymidine (3H-Td) and cultured overnight before being 
assayed for 3H-Td incorporation. Data represent the mean of triplicate samples ± 
s.e.m. *, P<0.01; **, P<0.001. YX. 
encoding β-catenin. After 48 hours, we stained cells with antibodies against the 
proliferation marker Ki67 and counted Ki67+ cells. As shown in Fig. 1B,C, β-catenin 
significantly increased the proliferation of GFAP+ cells but not of GFAP– cells. These 
results suggest that WNT responsiveness is associated with a GFAP+ population in the 
embryonic cerebellum.  
We have previously demonstrated that the postnatal cerebellum also contains 
NSCs31. These represent less than 1% of the cells in the cerebellum during the first 
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postnatal week, but can be identified based on their expression of prominin 1 (CD133) 
 
Figure 3:WNT signaling increases the proliferation of postnatal cerebellar 
stem cells but not granule neuron precursors. 
 (A,B) Prom1+ Lin− cells were sorted from P7 WT cerebellum and cultured in 
serum-free medium containing no factors (control) or recombinant WNT1 protein 
(A) or were infected with control (GFP) or β-catenin-IRES-GFP retroviruses (B). 
After 3 days, cells were stained with Ki67 antibodies to detect proliferation. (C) 
GFP+ cells (GNPs) were sorted from the cerebellum of P7 Math1-GFP mice and 
cultured in serum-free medium containing no factors (control), SHH or WNT1. 
After 48 hours, cells were pulsed with BrdU overnight and then stained with anti-
BrdU antibodies. Data represent the mean of eight (A), ten (B) or six (C) fields ± 
s.e.m. ***, P<0.001. YX and SNB. 
and their lack of neuronal and glial lineage markers (Prom1+ Lin–). To determine 
whether postnatal cerebellar NSCs are also responsive to WNT signaling, we sorted 
Prom1+ Lin– cells from P7 cerebellum and treated them with Wnt1 protein or infected 
them with β-catenin encoding retroviruses. Both Wnt1 protein and β- catenin increased 
the proliferation of these cells in vitro (Fig. 3A,B). By contrast, GNPs, which represent 
the majority of cells in the postnatal cerebellum [and express the transcription factor 
Math1 (Atoh1 – Mouse Genome Informatics)] did not proliferate in response to WNT1 
protein or β -catenin encoding retroviruses (Fig 3C; data not shown). Together, these 
studies suggest that WNT signaling is mitogenic for NSCs in the embryonic and 
postnatal cerebellum. 
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2.2.2 Activation of β-catenin expands NSCs in the cerebellar ventricular 
zone 
Having observed that cerebellar NSCs proliferate in response to WNT signaling 
in vitro, we tested their responsiveness to WNT signaling in vivo. We used Catnblox(Ex3) 
mice, in which exon 3 of the β-catenin gene is flanked by loxP sites104,117. When this 
exon is deleted by Cre recombinase, the resulting protein cannot be phosphorylated and 
degraded and therefore accumulates in the nucleus, where it constitutively turns on 
expression of WNT target genes. To activate WNT target gene expression in cerebellar 
NSCs, we crossed Catnblox(Ex3) mice with hGFAP-Cre mice118, which express Cre in the 
cerebellar VZ79,114,115. To verify that β-catenin was activated in the VZ of hGFAP-Cre; 
Catnblox(Ex3) (G-Cat) mice, we stained sections from E14.5 wild-type (WT) or G-Cat 
animals with anti- β-catenin antibodies. As shown in Fig. 4A-D, β-catenin was 
predominantly cytoplasmic in the VZ of WT mice, but was strongly expressed in nuclei of 
cells within the VZ of mutant mice. These data suggest that G-Cat mice have constitutive 
activation of the WNT pathway in the cerebellar VZ. 
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Figure 4:Activated β-catenin promotes proliferation in the cerebellar 
ventricular zone. 
 (A,B)β-catenin immunostaining (red) of E14.5 cerebellum reveals increased 
expression in the ventricular zone (VZ, arrowheads) of hGFAP-Cre; Catnblox(Ex3) (G-
Cat) mice (B) compared with WT mice (A). (C,D) Colocalization with DAPI (blue) 
highlights the cytoplasmic localization of β-catenin in WT mice (C) and nuclear 
localization in G-Cat mice (D). Arrowheads indicate the VZ. (E-H)Staining with anti-
BrdU (red, E,F) or anti-Ki67 (green, G,H) shows increased proliferation in the VZ of 
E14.5 G-Cat mice (F,H) compared with WT mice (E,G). (I,J)Number of Ki67+ cells 
per section in the VZ of WT and G-Cat mice at E14.5 (I) and at E13.5, E16.5 and P0 
(J). Data represent the mean (±s.e.m.) number of Ki67+ cells per section of six 
sections. *, P<0.01; **, P<0.001. Scale bars: 50µm. YX.  
To assess the effect of WNT signaling on proliferation in the embryonic 
cerebellum, we examined BrdU incorporation. E14.5 WT and mutant mice were exposed 
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to BrdU 30 minutes before being sacrificed, and cerebellar sections were stained with 
anti-BrdU antibodies. As shown in Fig. 4E,F, the VZ of mutant mice contained 
significantly more BrdU+ cells than that of WT mice (92±8 versus 38±5 cells/section). 
We also used anti-Ki67 to assess proliferation in WT and mutant cerebella (Fig. 4G-I). At 
E14.5, we found a 3-fold increase in the proportion of Ki67+ cells in the VZ of mutant 
mice compared with WT mice, confirming that WNT signaling increases proliferation in 
the embryonic VZ (Fig. 4I). Constitutively active β-catenin also caused increased 
proliferation at E13.5, E16.5 and P0, although the effects were most pronounced at 
earlier stages (Fig. 4J). These data suggest that activated β-catenin promotes 
proliferation in the cerebellar VZ during embryonic development. 
Previous studies have suggested that GFAP-expressing cells in the embryonic 
cerebellum include multipotent NSCs as well as mature astrocytic cells79,114,115. To 
determine whether the proliferating cells in the VZ of G-Cat mice were NSCs, we stained 
sections from E14.5 WT and mutant mice with antibodies specific for GFAP and the 
NSC marker Sox1. Mutant animals exhibited increased numbers of GFAP+ and Sox1+ 
cells in the embryonic cerebellar VZ (Fig. 5AD). We also co-stained sections from these 
animals with Sox1 and BrdU antibodies, and observed that almost all of the BrdU+ cells 
in the VZ expressed Sox1 (Fig. 5E,F). Similar results were obtained using antibodies 
specific for Sox2 (data not shown), supporting the notion that the proliferating cells in the 
VZ were NSCs. 
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Figure 5: Activated β-catenin increases the number of stem cells in the 
embryonic and neonatal cerebellum. 
(A-F) Cerebellar sections from E14.5 WT (A,C,E) or G-Cat (B,D,F) mice were 
stained with anti- GFAP antibodies (red in A,B) or anti-Sox1 (green) and anti-BrdU 
(red) antibodies (C-F). Note the increased expression of GFAP and Sox1 and the 
colocalization of Sox1 and BrdU in the mutant VZ. (G,H) Increased numbers of 
progenitors (G) and stem cells (H) in the cerebellum white matter in G-Cat mice 
compared with WT mice at P0. Cells isolated from the cerebellum of P0 WT and G-
Cat mice were stained with antibodies specific for prominin 1 (Prom1) and for 
lineage (Lin) markers (PSANCAM, O4 and TAPA-1). The percentage of Prom1+ 
progenitors (G) and Prom1+ Lin– stem cells (H) was analyzed by flow cytometry. 
Data represent mean (± s.e.m.) percentages from three separate experiments. *, 
P<0.01. Scale bars: 50µm. YX. 
To determine whether there was a similar expansion of NSCs in the postnatal 
cerebellum, we isolated cells from G-Cat mice at P0 and analyzed the percentage of 
Prom1+ cells (stem cells and progenitors) and Prom1+ Lin– cells (stem cells). Both 
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populations were increased ~6-fold in mutant compared with WT mice (Fig. 5G,H). 
Together, these studies suggest that activation of WNT signaling in GFAP+ cells 
expands the stem cell pool in the embryonic and postnatal cerebellum. 
2.2.3 Continued expression of β-catenin disrupts cerebellar development 
The fact that β-catenin promoted the proliferation of cerebellar NSCs suggested that it 
might lead to increased production of neurons and glia and expansion of the cerebellum. 
Unfortunately, almost all G-Cat mice died shortly after birth, making it impossible to 
study the long-term consequences of β-catenin activation in these animals. However, 
even at late embryonic and early postnatal stages the phenotype of mutant mice was not 
consistent with a purely mitogenic effect of WNT signaling. At E16.5, mutant mice had 
smaller cerebella than WT mice and, despite expansion of the VZ, exhibited a marked 
reduction in the thickness of the rhombic lip and EGL (Fig. 6A-D). At P0, mutant mice 
had an even more severe phenotype: their cerebella were significantly smaller than 
those of WT mice and lacked the foliation characteristic of this stage of development 
(Fig. 7A,B). Moreover, staining of the cerebellum with lineage markers revealed marked 
defects in neuronal and glial differentiation. The region normally occupied by the EGL 
contained few cells and none of these expressed Ki67 or Pax6, which are markers of 
proliferating GNPs (Fig. 7A-D). Some calbindin+ Purkinje cells were present, but these 
were very disorganized compared with those in the WT cerebellum (Fig. 7E,F). Pax2+  
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Figure 6:Activation of β-catenin in the ventricular zone disrupts embryonic 
cerebellar development. 
(A-D) Cerebella of E16.5 WT (A,B) and G-Cat (C,D) mice were sectioned and 
stained with DAPI (A,C) or Hematoxylin and Eosin (B,D). Although the thickness of 
the VZ (arrowhead) is increased in the mutant, the overall size of the cerebellum 
and the thickness of the external granule layer (arrow) are reduced. Scale bars: 50 
µm. YX. 
 
interneuron progenitors (Fig. 7G,H) and glial cells [S100β and BLBP (Fabp7 – Mouse 
Genome Informatics) staining, Fig. 7I-L] were detectable but in reduced numbers, and, in 
the case of glia, with aberrant localization and morphology. Thus, the increased NSC 
proliferation induced by β catenin is accompanied by marked defects in neuronal and 
glial differentiation. 
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Figure 7:Activation of β-catenin in stem cells impairs neuronal and glial 
differentiation. 
(A-L)Sections from P0 WT (A,C,E,G,I,K) and G-Cat (B,D,F,H,J,L) cerebella were 
stained with antibodies specific for Ki67 (A,B) to label proliferating cells, Pax6 
(C,D) to label granule neuron precursors (GNPs), calbindin (E,F) to mark Purkinje 
neurons, Pax2 (G,H) to detect stellate and basket interneuron precursors, and 
S100β (I,J) or BLBP (K,L) to detect glial cells. All sections were counterstained 
with DAPI. Note the marked reduction in progenitors and differentiated cells in G-
Cat mice. Scale bar: 50µm. YX and SNB. 
 
The dramatic loss of neuronal progenitors in G-Cat mice could reflect a failure of 
NSCs to differentiate along the neuronal lineage or the reduced proliferation or survival 
of neuronal progenitors once they have been generated. To test whether expression of 
β-catenin in GNPs impairs their growth or survival, we crossed Catnblox(Ex3) mice with 
Math1-Cre transgenic mice, which express Cre in cells of the granule lineage79,115. 
Analysis of cerebella from Math1-Cre; Catnblox(Ex3) (M-Cat) mice at E14.5 revealed an 
intact EGL with relatively normal numbers of proliferating (Ki67+) cells (Fig. 8A,B). At P0, 
proliferation could be detected in the anterior EGL, but few proliferating cells were seen 
on the posterior surface of the cerebellum (Fig.8C,D). Although these animals exhibited 
normal viability and no overt signs of neurological dysfunction, their cerebella were 
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smaller and contained fewer lobes than those of WT animals (Fig. 8E,F). These results 
suggest that expression of activated β-catenin does not prevent formation of the EGL, 
but might impair proliferation or long-term survival of GNPs. 
 
Figure 8: Overexpression of β-catenin in granule neuron precursors 
reduces cerebellar size and foliation. 
(A-F) Cerebellar sections from WT (A,C,E) and Math1-Cre; Catnblox(Ex3) (M-
Cat: B,D,F) mice were stained with Ki67 antibodies to detect proliferation at (A,B) 
E14.5, (C,D) P0 and (E,F) P8. Scale bars: 50 µm. YX. 
 
2.2.4 Deletion of Apc impairs the function of cerebellar NSCs 
A possible explanation for the defects in G-Cat mice is that the non-degradable 
(exon 3-lacking) β-catenin protein in these animals leads to high levels of WNT pathway 
activation, which might be toxic for stem cells and progenitors. To examine this 
possibility, we used an alternative approach to activating WNT signaling in these cells: 
inactivation of the Apc protein. Apc is part of the ‘destruction complex’ that targets β-
catenin for degradation in the absence of WNT stimulation; inactivating mutations in Apc 
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allow for accumulation and nuclear translocation of β-catenin, thereby promoting WNT 
target gene transcription119. 
To study the consequences of Apc inactivation for cerebellar NSCs we crossed 
hGFAP-Cre mice with Apclox/lox mice, which carry loxP sites surrounding exon 14 of the 
Apc gene. This exon is crucial for interaction of Apc with β-catenin and axin (another 
component of the destruction complex), so following Cre-mediated deletion Apc is 
unable to target β-catenin for degradation. To verify that this approach resulted in WNT 
pathway activation, we stained cerebella from E14.5 hGFAP-Cre; Apclox/lox (G-APC) mice  
with anti- β-catenin. Deletion of Apc exon 14 resulted in nuclear accumulation of 
 
Figure 9: Inactivation of Apc in the cerebellar ventricular zone leads to WNT 
pathway activation and proliferation. 
(A-D) Cerebellar sections from E14.5 WT (A,C) and G-APC (B,D) mice were 
stained with DAPI (blue) and anti-β-catenin (red, A,B) or anti-Ki67 (red, C,D) 
antibodies to detect WNT pathway activation and proliferation, respectively. Note 
the accumulation of nuclear β-catenin (colocalization with DAPI in B) and 
increased proliferation (Ki67+ cells in D) in the VZ of G-APC mice. Arrowheads 
indicate VZ. Scale bar: 50 µm. SNB. 
 
β-catenin in the VZ (Fig. 9A,B). Similar to G-Cat mice, G-APC mice showed increased 
proliferation in the VZ at E14.5 (Fig. 9C,D). G-APC mice also died shortly after birth 
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andhad much smaller cerebella than WT littermates at P0 (Fig. 10). Moreover, whereas 
WT cerebella contain proliferating (Ki67+) Pax6+ GNPs on their surface (Fig. 10A,C), 
mutant cerebella had few such cells (Fig. 10B,D). As with G-Cat mice, staining of G-APC 
cerebella with anti-calbindin antibodies revealed disorganization of Purkinje neurons 
(Fig. 10E,F). Staining for Pax2 (Fig. 10G,H) and S100β (Fig. 10I,J) also showed marked 
reductions in the numbers of interneurons and glia in mutant cerebella. These results 
suggest that WNT pathway activation – either through stabilization of β -catenin or loss 
of Apc – causes increased proliferation of NSCs and defective differentiation of these 
cells into neuronal and glial progenitors. 
 
Figure 10: Deletion of Apc in stem cells also impairs differentiation. 
(A-J) Sections from P0 WT (A,C,E,G,I) and hGFAP-Cre; Apclox/lox (G-APC; B,D,F,H,J) 
cerebella were stained with antibodies specific for Ki67 (A,B) to label proliferating 
cells, Pax6 (C,D) to label GNPs, calbindin (E,F) to mark Purkinje neurons, Pax2 
(G,H) to detect stellate and basket interneuron precursors, and S100β (I,J) to 
detect glia cells. Sections were counterstained with DAPI. Note the marked 
reduction in progenitors and differentiated cells in G-APC mice. Scale bar: 50µm. 
SNB. 
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2.2.5 Overexpression of β-catenin impairs NSC self-renewal and 
differentiation in vitro 
The above studies suggest that WNT pathway activation causes cerebellar NSCs 
to proliferate but does not result in increased numbers of differentiated cells. To 
understand the basis for this defect, we examined the effects of β-catenin on self-
renewal. Cells were isolated from WT and G-Cat mice at P0 and cultured in serum-free 
medium containing bFGF (FGF2) and EGF. As we have shown previously31, Prom1+ 
Lin– cells from WT mice form neurospheres under these conditions (Fig. 11A,C). By 
contrast, NSCs from mutant cerebellum formed neurospheres at a significantly lower 
frequency (P<0.01; Fig. 11B,C). Moreover, mutant neurospheres were smaller and could 
not give rise to secondary neurospheres, indicating a defect in self renewal. Similar 
results were observed when NSCs were isolated from the cerebellum at E14.5 (data not 
shown). Thus, constitutive activation of β-catenin in GFAP+ cells causes transient 
proliferation of NSCs but impairs their ability to undergo self-renewal. This defect in self-
renewal could explain the reduction in cerebellar mass in these mice. 
 
Figure 11: β-catenin-expressing stem cells exhibit aberrant self-renewal 
and differentiation in vitro. 
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(A,B) Prom1+ Lin– cells were sorted from P0 WT (A) or G-Cat (B) mouse 
cerebellum and cultured at clonal density in serum-free medium containing 25 
ng/ml EGF and bFGF for 7 days before being photographed under bright-field. 
Passageable neurospheres were consistently obtained from WT but not from 
mutant cerebellum. (C) Average neurosphere numbers (±s.e.m.) per field from 
eight fields in P0 WT or G Cat cerebellum. (D,E)Prom1+ Lin– cells were sorted 
from P0 WT (D) or G-Cat (E) cerebellum and cultured for 3 days in medium 
containing 1% FBS. Cells were stained with antibodies specific for the neuronal 
marker Map2 (red) and the glial cell marker S100β (green). (F) Quantitation (mean 
± s.e.m.) of Map2/S100β staining from five fields. *, P<0.01; **, P<0.001. Whereas 
WT stem cells differentiated predominantly into neurons, G-Cat showed a marked 
skewing toward glial lineages. Scale bars: 25µm in A,B; 50µm in D,E. YX and SNB.  
 
We next asked whether WNT signaling affects the differentiation of cerebellar 
NSCs in vitro. Although NSC differentiation is often assayed by generating neurospheres 
and then withdrawing growth factors, the impaired neurosphere-forming capacity of 
mutant NSCs precluded such analysis. Instead, we isolated Prom1+ Lin– cells from P0 
WT and mutant mice and cultured them in the presence of 1% FBS for 3 days. Cells 
were stained with antibodies specific for Map2 (Mtap2 – Mouse Genome Informatics; to 
detect neuronal differentiation) and S100β (to detect glial differentiation). Whereas NSCs 
from WT animals predominantly generated neurons (60% Map2+, 22% S100 β +), NSCs 
from mutant mice almost exclusively generated glia (7% Map2+, 80% S100 β +) (Fig. 
11D-F). These data, which are consistent with the marked depletion of neurons in G-Cat 
mice in vivo, suggest that activation of β-catenin in GFAP+ cells markedly alters the 
differentiation potential of postnatal cerebellar NSCs. 
2.2.6 Loss of β-catenin causes self-renewal defects and increased 
neuronal differentiation in vitro 
Given the effects of β-catenin overexpression on stem cell self-renewal and 
differentiation, we examined the effects of loss of β- catenin on these processes. We 
used Catnblox(ex2-6) mice, in which exons 2-6 of β-catenin are flanked by loxP sites. 
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Introduction of Cre into these cells results in excision of exons 2-6 and loss of β-catenin 
expression. Prom1+ Lin– cells were isolated from Catnblox(ex2-6) mice at P0, infected with 
control (GFP) viruses (Fig. 12A) or Cre-IRES-GFP viruses (Fig. 12B) and cultured in 
stem cell media in the presence of bFGF and EGF. After 10 days, total and GFP-
expressing neurospheres were counted. The percentage of GFP+ neurospheres was 
significantly lower in Cre-infected cultures than in control cultures (Fig. 12A,C). 
Additionally, the neurospheres from Cre-infected cells were smaller and more irregularly 
shaped than those from control cells (Fig. 12B,C). The fact that both gain and loss of β-
catenin result in decreased neurosphere-forming capacity suggests that the level of β-
catenin is crucial for maintenance of self-renewal capacity. 
We then asked whether loss of β-catenin affects the differentiation of stem cells. 
Prom1+ Lin– cells were isolated from Catnblox(ex2-6) mice, infected with viruses, and 
maintained in 3% FBS-containing media for 3 days to allow for differentiation. Cells were 
then stained for Map2 (Fig. 12D,E) and S100 β (Fig. 12F,G) to mark differentiated  
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Figure 12:  Loss of β-catenin impairs self-renewal and increases neuronal 
differentiation. 
(A-C) Prom1+ Lin− cells were isolated from P0 Catnblox(ex3)/+ mice and 
infected with control (GFP) (A) or Cre-IRES-GFP (B) viruses overnight. Cells were 
collected and replated at low density (2000 cells/ml) and cultured for 7 days under 
neurosphere-promoting conditions. (A,B) Representative images of GFP-
expressing neurospheres. (C) Total neurospheres and GFP+ neurospheres were 
counted for each condition. The percentage of GFP+ neurospheres was calculated 
from five replicates and significance was determined using t-test. (D-G) Prom1+ 
Lin− cells were isolated from Catnblox(ex3)/+ mice and infected with control (D,F) or 
Cre-IRES-GFP (E,G) viruses. Cells were fixed after 3 days in culture and stained 
with antibodies against Map2 (D,E) to mark neuronal cells or S100 (F,G) to label 
glial cells. (H) Percentage of GFP/Map2 and GFP/S100 were calculated from three 
replicates. *, P<0.01. Scale bar: 50 µm. SNB. 
 
neuronal and glial cells. Interestingly, we found an increase of Map2+ cells among Cre-
infected cells compared with control cells (Fig. 12D,E,H). Loss of β-catenin had no effect 
on the percentage of S100 β + cells as compared with control cells (Fig. 12F-H). These 
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data suggest that loss of β-catenin skews stem cell differentiation toward neuronal 
lineages. 
2.2.7 Activation of β-catenin causes increased expression of BMPs and p21 
Our studies suggested that WNT signaling promotes the proliferation of 
cerebellar NSCs but interferes with their capacity for self-renewal and differentiation. To 
gain insight into the molecular basis for these findings, we isolated RNA from WT and 
mutant Prom1+ Lin– cells and analyzed expression of WNT target genes and regulators 
of proliferation and self-renewal. RT-QPCR analysis revealed no consistent differences 
in expression of the polycomb transcription factor Bmi1 or the Notch target genes Hes1 
and Hes5 (Fig. 13A), each of which has been implicated in NSC self-renewal120-122. By 
contrast, expression of c-Myc, a common target of the WNT pathway123,124, was elevated 
in NSCs isolated from G-Cat mice (Fig. 13A).  
Although increased expression of c-Myc provided a potential explanation for the 
increase in proliferation induced by β-catenin, the basis for the defects in self-renewal 
and differentiation in G-Cat mice remained unclear. Previous reports have suggested 
that in neuroepithelial progenitors from the dorsal CNS, WNT signaling not only induces 
proliferation but also increases the expression of bone morphogenetic proteins 
(BMPs)106. BMPs, in turn, inhibit WNT induced proliferation and self-renewal106 and 
promote glial differentiation125,126. This led us to examine whether the self-renewal and 
differentiation defects in G-Cat mice are mediated by BMPs. As shown in Fig. 11A, 
mutant cells exhibited a significant increase in the expression of Bmp2 and Bmp7. In 
addition, expression of the cyclin-dependent kinase inhibitor p21 (Cdkn1a – Mouse 
Genome Informatics), which is a common target of BMPs, was also markedly elevated in 
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NSCs from G-Cat mice. These findings suggest that overexpression of β-catenin in 
NSCs results in increased BMP/p21 signaling. 
 
 
Figure 13: Stem cells from G-Cat mice express elevated levels of BMPs and 
p21. 
(A) Quantitative RT-PCR was performed on Prom1+ Lin– cells isolated from P0 WT 
and G-Cat mice using primers for the indicated genes. Mice from four litters were 
analyzed, and after normalization to actin the expression of each gene in G-Cat 
cells was compared with that in WT littermates to calculate a ratio of gene 
expression for each litter. Data are plotted as the mean (±s.e.m.) log ratio (G-
Cat:WT). *, P<0.02; **, P<0.05. (B-D) Noggin promotes neuronal differentiation. 
Prom1+ Lin– cells were isolated from P0 G-Cat mice, treated with noggin protein 
(200 ng/ml) and cultured for 3 days in serum-containing media to promote 
differentiation. Cells were stained for Map2 (red) and S100β (green). Quantitation 
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(mean ± s.e.m.) of Map2/S100β staining is from six fields. *, P<0.01. Scale bar: 
50µm. SNB. 
 
To determine whether the BMP pathway regulates self-renewal of cerebellar 
stem cells, we performed both gain- and loss-of function experiments. Prom1+ Lin– cells 
from WT mice were cultured at low density in the presence of growth factors along with 
recombinant Bmp2 or Bmp7 (200 ng/ml). After 7 days, stem cells treated with either 
Bmp2 or Bmp7 showed a marked decrease in neurosphere formation compared with 
control cells (Fig. 14A). Conversely, Prom1+ Lin– stem cells treated with the BMP 
inhibitor noggin produced more neurospheres than control cells (Fig. 14B). Cells infected 
with viruses encoding short hairpin RNA specific for p21 (p21shRNA) also showed 
increased neurosphere formation (Fig. 14B). These studies suggested that BMP 
signaling interferes with the self-renewal of cerebellar stem cells. 
 
Figure 14: BMP signaling impairs stem cell self-renewal in vitro. 
(A) WT Prom1+ Lin− cells were isolated at P0 and plated at low density for 7 
days in serum-free media containing bFGF and EGF, without (control) or with 
BMP2 (200 ng/ml) or BMP7 (200 ng/ml). (B) WT Prom1+ Lin− cells from P0 WT mice 
were infected with GFP viruses alone (GFP), infected with GFP viruses and treated 
with noggin (200 ng/ml), or infected with p21shRNA viruses (without noggin) and 
cultured in serum-free medium containing bFGF and EGF. After 7 days, noggin-
treated cells or p21-infected cells generated 2- to 2.5-fold more neurospheres than 
GFP-infected cells. SNB. 
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To determine whether increased BMP signaling could explain the impaired self-
renewal and differentiation of stem cells from G-Cat mice, we isolated Prom1+ Lin– cells 
from P0 G-Cat mice and treated them with noggin or p21shRNA. Neither noggin 
treatment nor p21 knockdown was able to rescue the neurosphere defect in these cells 
(data not shown). However, noggin significantly increased neuronal differentiation and 
slightly decreased glial differentiation of G-Cat cells (Fig. 13B-D). Knockdown of p21 
promoted the neuronal differentiation of WT stem cells (Fig. 15AE), although it was not 
able to rescue the differentiation defects in G-Cat stem cells (Fig. 15F-J). Together, 
these data suggest that the BMP pathway regulates the self renewal and differentiation 
of WT stem cells, but is not sufficient to account for the defects in self-renewal and 
differentiation seen in β –catenin overexpressing mice. 
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Figure 15: Knockdown of p21 promotes neuronal differentiation in vitro. 
(A-D,F-I) Prom1+ Lin− cells from P0 WT or G-Cat mice were infected with 
GFP (A-D) or Cre-IRES-GFP (F-I) viruses and cultured for 3 days in serum-
containing medium to promote differentiation. Cells were stained for Map2 (red) or 
S100 (green). (E) Quantification of Map2/GFP+ or S100/GFP+ cells from WT stem 
cells. (J) Quantification of Map2/GFP+ or S100/GFP+ cells from G-Cat stem cells. 
Scale bar: 50 µm. YX and SNB.  
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2.3 Discussion 
WNT signaling plays a crucial role in the development of many parts of the CNS 
and, in particular, has been implicated in the establishment of the midbrain hindbrain 
boundary that gives rise to the cerebellum. The fact that a subset of human 
medulloblastomas contains activating mutations in β -catenin or loss-of function 
mutations in APC suggests that WNT signaling might also be mitogenic for a population 
of cells in the developing cerebellum. To identify such a population, we screened cells 
from various stages of cerebellar development for WNT responsiveness. Our studies 
suggest that NSCs from the embryonic and neonatal cerebellum are capable of 
proliferating in response to WNT pathway activation. However, the increased 
proliferation of these cells in vivo is accompanied by marked defects in self-renewal and 
differentiation. Based on these studies, we conclude that WNT signaling induces 
proliferation but impairs differentiation of cerebellar stem cells. 
Although WNT signaling is known to be mitogenic for NSCs in other parts of the 
CNS102-104, it has not been shown to promote proliferation in the cerebellum. We 
observed WNT pathway induced proliferation both in vitro, upon treatment of NSCs with 
WNT protein or infection with β -catenin-encoding retroviruses, and in vivo, following 
activation of β-catenin or deletion of Apc using the hGFAP-Cre transgene. It is 
interesting that in previous studies examining the effects of WNT pathway activation in 
the CNS, there was no mention of mitogenic effects in the cerebellum102-104; it is unclear 
whether these studies did not examine this region, or whether the promoters used 
[nestin, Brn4 (Pou3f4)] did not target the same population of NSCs at the same stage of 
development. However, recent studies have demonstrated that deletion of β-catenin 
results in loss of the cerebellar vermis74, and these investigators speculated that this 
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might result from inadequate proliferation. Our studies support this notion and suggest 
that, at least early in development, the mitogenic effects of WNT signaling might 
contribute to expansion of the cerebellar primordium. 
Although activation of WNT signaling promotes proliferation of NSCs, this  
proliferation appears to be transient: G-Cat mice exhibit increased numbers of dividing 
Sox1+ cells in the VZ at embryonic stages, but these cells do not expand indefinitely in 
vivo and cannot form neurospheres in vitro. One explanation for the failure of mutant 
NSCs to form neurospheres is that activation of the WNT pathway allows cells to 
proliferate at high density but does not favor growth under neurosphere-forming 
conditions (at low density in EGF and bFGF). Alternatively, it is possible that aberrant 
expression of β-catenin affects the cell surface expression of cadherins and thereby 
interferes with cell-cell interactions that are necessary for cells to grow as 
neurospheres127 . Finally, WNT pathway activation, while promoting proliferation, might 
change the mode by which NSCs divide; for example, by shifting the balance from 
symmetric renewal (whereby a stem cell gives rise to two stem cells) or asymmetric 
division (whereby stem cells give rise to one stem cell and one differentiated cell) to 
symmetric differentiation (wherein both progeny undergo differentiation). This might 
explain both the inability to form neurospheres in vitro and the lack of prolonged 
expansion in vivo. 
In addition to its effects on proliferation and self-renewal, WNT pathway 
activation also severely disrupts NSC differentiation. In vitro, this is manifest as a  
marked skewing toward glial cells at the expense of neuronal lineages. In vivo the 
effects are even more striking, with a reduction in most classes of neurons and a 
decrease in the overall size of the cerebellum. In principle, these defects could reflect 
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either a failure of NSCs to commit to neuronal lineages or the impaired growth and 
survival of neuronal progenitors or neurons once they are formed. The fact that few 
Purkinje and granule neurons can be detected in the cerebellum of G-Cat mice, and that 
purified NSCs from these animals differentiate predominantly into S100 β + glia, support 
the former possibility. However, our observations that M-Cat mice have a normal EGL 
but produce fewer GNPs suggest that impaired proliferation might also contribute to the 
reduction in the number of neurons, at least in the granule lineage. Consistent with this, 
a recent study has demonstrated that loss of Apc in GNPs results in inhibition of cell 
proliferation128. Although WNT signaling promotes neurogenesis in many parts of the 
nervous system103,108,129, its ability to interfere with neuronal differentiation in the 
cerebellum is not without precedent. For example, β -catenin has been reported to inhibit 
neuronal differentiation in embryonic stem cells and in progenitors within the spinal 
cord106,130. Likewise, in the hematopoietic system, activation of β -catenin increases 
proliferation of stem cells131,132 but can also cause a profound block in differentiation 
along myeloid, lymphoid and erythroid lineages133,134. Finally, stabilization of β catenin in 
the airway epithelium blocks Clara cell differentiation135. Thus, impaired differentiation is 
not an uncommon effect of WNT pathway activation. 
To understand the mechanisms by which β-catenin alters NSC renewal and 
differentiation, we examined expression of genes that have been identified as targets of 
the WNT pathway in other cells. Our results showed that c-Myc, a common target of 
WNT signaling123, was elevated in NSCs from G-Cat mice compared with control NSCs. 
Increased expression of c-Myc could account for the NSC proliferation we observed in 
embryonic and postnatal G-Cat mice, but is difficult to reconcile with the defects in self-
renewal and differentiation observed in these animals. In this regard, our finding that 
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NSCs from G-Cat mice express increased levels of Bmp2 and Bmp7 might be important. 
BMPs have been reported to be induced by β-catenin and to counteract the mitogenic 
effects of canonical WNT signaling in the dorsal neural tube106. In addition, BMPs 
frequently induce expression of the cyclin-dependent kinase inhibitor p21136-138 which 
has also been shown to inhibit self renewal of NSCs139,140. The fact that we observe 
significant upregulation of both BMPs and p21 raises the possibility that this pathway 
contributes to the self-renewal defects in G-Cat mice. However, our inability to rescue 
these defects with noggin or p21shRNA implies that other pathways might be involved 
as well. Notably, in addition to their inhibitory effects on proliferation, BMPs are also 
potent inducers of glial differentiation125,141. Thus, increased expression of BMPs might 
also explain the skewing of NSC differentiation toward the glial lineage that we observed 
in vitro and in vivo. Our observation that noggin can restore neuronal differentiation of G-
Cat stem cells supports a role for BMP signaling in this process. 
Although G-Cat mice do not live long enough to develop brain tumors, our 
studies have implications for understanding WNTassociated medulloblastoma. First, our 
observation that β-catenin does not promote the proliferation of GNPs in vitro or in vivo 
suggests that unlike Shh-associated tumors115 WNT-associated tumors are unlikely to 
arise from GNPs. By contrast, the fact that WNT is mitogenic for NSCs in the cerebellar 
VZ and postnatal white matter raises the possibility that these represent cells of origin for 
the disease. The idea that SHH- and WNT-driven tumors come from different cells of 
origin is supported by genomic analysis14,18,142,143, which indicates that these tumors 
have very distinct gene expression profiles. Although recent studies have shown that 
WNT-associated tumors can arise from progenitors in the dorsal brainstem24, our results 
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raise the possibility that some of these tumors could also originate from embryonic or 
postnatal NSCs in the cerebellar VZ. 
Whatever the cell of origin for WNT pathway tumors, it seems likely that 
activation of WNT signaling alone is insufficient to drive tumorigenesis. This is supported 
by our own studies, in which activation of β-catenin or deletion of Apc drives proliferation 
but not long-term self-renewal of NSCs. Similarly, activation of β-catenin in BLBP-
expressing cells does not cause tumors on its own, but can synergize with loss of p53 
(Trp53) to promote medulloblastoma formation24. Interestingly, analysis of human WNT 
pathway tumors indicates that they frequently lose one copy of chromosome 613,14, 
suggesting that loss of a gene on this chromosome might be a key event in 
tumorigenesis. Identification of WNT responsive cells in the cerebellum will facilitate 
analysis of specific genes that may cooperate with the WNT pathway to promote 
uncontrolled growth or tumor formation. 
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3. Survivin as a therapeutic target in Sonic hedgehog-
driven medulloblastoma 
3.1 Introduction 
As was introduced in previous chapters, medulloblastoma (MB) is the most 
common malignant brain tumor in children1. Intensive therapy –including surgery, cranio-
spinal radiation and high dose chemotherapy – has improved 5-year survival rates2, but 
almost a third of MB patients still die from their disease, and survivors suffer severe long 
term side effects that affect their quality of life23. Thus, safer and more effective therapies 
are needed for this disease. 
In recent years, targeted therapies have begun to be evaluated in patients with 
MB. For example, with the recognition that a subset of MBs results from mutations in the 
Sonic Hedgehog (SHH) pathway143, antagonists of Smoothened (SMO), an activator of 
the pathway, have advanced into clinical trials for the disease. Although initial reports 
suggested that these agents can inhibit tumor growth20, as with many targeted therapies, 
resistance develops quickly144. Moreover, patients who have SHH pathway mutations 
downstream of SMO do not respond to these agents at all145.  Thus, even for SHH-
driven MBs, additional approaches are necessary.   
Finding novel therapeutic targets for MB depends on identification of genes that 
are critical for tumor growth and survival. One gene that is highly expressed in human 
MB and could represent a potential new therapeutic target is Survivin (also known as 
baculoviral inhibitor of apoptosis repeat-containing 5, or BIRC5).  
Survivin was first identified in human B cell lymphomas146 and is a member of the 
IAP family that regulates both cell cycle progression and cell survival147,148. It contains 
one baculovirus IAP repeat (BIR), which is a hallmark of all IAPs and is required for their 
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ability to inhibit apoptosis. Survivin lacks any of the other functional domains commonly 
found in IAPs, such as a caspase recruitment domain149,150. Survivin is ubiquitously 
expressed during embryonic and fetal development, but is undetectable in most 
differentiated adult tissues151. Germline knockout in the mouse leads to lethality at E3.5, 
supporting an essential role in development152. Tissue specific knockouts have revealed 
important functions for Survivin in development of pancreatic beta cells153,154 and 
endothelial cells155, and deletion in neural progenitors results in decreased brain size 
and perinatal lethality, suggesting critical roles in neural development as well156. Recent 
studies have suggested a role for survivin in a restricted set of proliferative adult tissues 
as well157, namely CD34+ hematopoietic stem cells158, T lymphocytes159,160, 
neutrophils161, and vascular endothelial cells162,163.  
 In context of the cell cycle, Survivin functions primarily as a critical component of 
the chromosomal passenger complex (CPC), which includes Survivin, Aurora B, 
INCENP (inner centromere protein) and Borealin164. The CPC binds to centromeres and 
corrects the alignment of chromosomes at metaphase, and then migrates to the spindle 
midzone in late mitosis to enable completion of cell cleavage.164-166 If Survivin (or any of 
the other CPC proteins) is suppressed, the complex does not associate with the 
centromere, and the metaphase spindle assembly checkpoint is abrogated164,167. 
.Survivin in is critical for mediating localization of this complex throughout mitosis and 
subsequent activation of Aurora B by its ability to recognize and bind phosphorylated 
histone H3 (Thr3), which recruits the CPC to chromosomes 168-171.  In addition, absence 
of CPC proteins interferes with cell cleavage172. Thus, Survivin function is critical for 
mitosis. It has also been suggested that Survivin regulates microtubule dynamics, 
possibility independent of its participation in the CPC173,174. Finally, Survivin contributes 
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to regulation of the G1-S transition in T lymphocytes159, hematopoietic progenitors175,176, 
and hepatoma cells177, although the mechanism is not as well understood. 
Consistent with structural similarity to other IAPs, survivin is also involved in cell 
survival and apoptosis inhibition. Overexpression of survivin is associated with inhibition 
of cell death via both intrinsic and extrinsic apoptosis pathways in vitro and cell death 
inhibition in vivo178-183. Similarly, loss of survivin expression/function sensitizes cells to 
various apoptotic stimuli, including FAS ligand, overexpression of BAX, p53, caspases-3, 
-7, -8, and cytotoxic drugs184-187. Although initial data suggested that this involved direct 
inhibition of caspase activity185,188 (the effector enzymes of apoptosis) current evidence 
indicates that, as with most IAPs, Survivin regulates their activity indirectly189-192. The 
cytoprotective effect of survivin instead arises from interactions with cofactors or 
effectors.  Survivin can form a complex with HBXIP (Hepatitis B X-interacting protein), 
which then binds to pro-caspase 9 and prevents its recruitment to the apoptosome193. It 
can also enhance the activity of other IAPs, either through direct binding to XIAP (X-
linked inhibitor of apoptosis)194 or by interacting with SMAC-Diablo (second 
mitochondria-derived activator of caspases/direct IAP binding protein with low pI), which 
displaces SMAC-bound IAPs, allowing them to inhibit apoptosis195,196.  A subfraction of 
survivin is also imported to the mitochondria, where it can bind proapoptotic factors and 
inhibit mitochondrial apoptosis185.  
In addition to its roles in normal development, survivin seems to be an important 
player in tumorigenesis. Survivin is expressed in many human cancers (both adult and 
pediatric) with minimal expression in normal adult differentiated tissues147,  making a 
highly cancer-specific marker. Importantly, its expression is correlated with poor clinical 
outcome in numerous malignancies, including non-small cell lung cancer (NSCLC)197, 
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breast cancer198, leukemia199,200, neuroblastoma201 and glioma202. Recently, it has also 
been identified as a biomarker for bladder203 and breast cancer204,205 and to be a critical 
mediator of early stages of tumor development and progression in liver and prostate 
cancer206,207. Additionally, Survivin interacts with multiple signaling networks critical for 
tumorigenesis, making it a nodal protein and ideal target for therapies.  For example, 
Survivin expression is regulated by numerous oncogenes and tumor suppressors 
commonly mutated in cancer such as p53181,208,  Ras209, and Myc210 and binding sites for 
transcription factors such as Stat3, E2F proteins, and NFkB have been mapped to the 
Survivin promoter201. Survivin has also been implicated in promoting angiogenesis in 
tumors211,212 and inhibition of survivin in ECs by antisense oligonucleotide163 or 
introduction of a mutant form of survivin67 causes vascular regression during tumor 
angiogenesis. Because of its high expression in tumors and minimal expression in most 
adult tissues151, a number of approaches have been developed to inhibit its expression 
and function. These include small molecule antagonists, dominant negative mutants, 
antisense oligonucleotides, and immunotherapy213-217. Numerous studies across cancer 
types have demonstrated the efficacy of inhibiting Survivin on impeding tumor growth 
and survival both in vitro and in vivo147. Some of these targeting approaches have now 
advanced to phase 1 and 2 clinical trials for a range of tumor types, including prostate 
cancer218,219, lymphoma219, leukemia220, melanoma221-223, breast cancer223,224, and 
NSCLC223-225.  
Survivin has not yet been studied extensively in the context of MB. Although 
some studies have suggested that elevated expression is linked to poor prognosis226-228, 
little is known about its role in MB growth and survival. Using an animal model of SHH-
driven MB, we now show that Survivin is highly expressed in tumors and absent from 
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normal adult cerebellum. Moreover, through both genetic deletion and pharmacological 
inhibition we demonstrate that Survivin is critical for proliferation and survival of mouse 
and human SHH driven MB cells. Finally, Survivin antagonists impair growth of MB in 
vivo, highlighting the potential of Survivin as a therapeutic target in patients with MB.  
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3.2 Results 
3.2.1 Survivin is highly expressed in medulloblastomas from Ptch mutant 
mice 
To determine whether Survivin could represent a target in SHH driven MB, we 
isolated RNA from Ptch mutant tumors and examined survivin expression using real time 
PCR. High levels of survivin were detected in all tumors and in granule neuron 
precursors (GNPs), the progenitors from which these tumors are thought to arise115 
(Figure 16A). Importantly, expression could not be detected in normal adult cerebellum. 
Similar results were seen when Survivin protein was examined by immunoblotting 
(Figure 16B). Staining of tissue sections revealed Survivin expression in the nuclei of 
tumor cells (abrogated by blocking peptide (Figure 16D)), and minimal staining in normal 
adult cerebellum (Figure 16C-F). These data indicate that Survivin is highly expressed in 
Ptch mutant tumors, raising the possibility that it might play an important role in tumor 
growth or maintenance. 
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Figure 16: Survivin is expressed in Ptch mutant tumors. 
(A) RNA and protein from Ptch mutant MB cells, P7 GNPs and adult cerebellum 
were analyzed for Survivin expression using real time PCR (A) and by western 
blotting (B). Survivin is highly expressed in tumors and GNPs, but not in adult 
cerebellum. Error bars  in (A) represent 95% confidence interval calculated using 
sum of the squares method (p<0.02 by ANOVA and post hoc student’s t-test). (C-
F) Tissue sections from Ptch mutant tumor and normal adult cerebellum were 
stained with anti-Survivin antibodies alone (C,E) or with anti-Survivin antibodies 
that were pre-incubated for 30 min with Survivin blocking peptide (D,F). Survivin is 
highly expressed in tumor cells with minimal expression in adult cerebellum. Inset 
in (C) is 4x magnification of positive staining. Scale bars represent 50 µM.  Data 
are representative of 3 experiments. 
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3.2.2 Survivin is critical for MB cell proliferation and cell cycle progression 
To investigate the importance of Survivin for growth of MB cells, we first utilized a 
genetic approach. Survivinfl/fl  mice160, in which the survivin gene is flanked by loxP sites, 
were crossed with Ptch+/- mice, to generate tumors in which survivin can be deleted by 
Cre recombinase. We confirmed efficient deletion of survivin by isolating tumor cells 
from Survivinfl/fl;Ptch+/- (SP) mice and infecting them with Cre retroviruses. After 48hrs, 
survivin expression was significantly reduced (by 82%) in Cre-infected cells compared to 
control (GFP-infected) cells (Figure 17A). We then looked at the effect of survivin loss on 
proliferation. After Cre-mediated deletion of survivin from SP tumor cells, thymidine 
incorporation was decreased by almost 90% (Figure 17B). Importantly, when tumor cells 
from SurvivinWT mice were infected with Cre viruses, there was no appreciable difference 
in proliferation compared to control cells (Figure 17C), indicating that the decreased 
thymidine incorporation observed in SP tumor cells was not due to non-specific toxicity 
of the Cre virus.  Similarly, loss of survivin in normal GNPs caused a decrease in 
proliferation. (Figure 18A-C). To address whether loss of survivin affects cell cycle 
progression, we isolated cells from SP tumors, infected them with Cre or GFP viruses, 
and performed cell cycle analysis (Figure 17D,E). survivin deletion led to a marked 
accumulation of cells in the G2/M phases of the cell cycle (39% of Cre-infected cells vs. 
9.5% of control cells in G2/M).  Together, these data demonstrate that Survivin is 
necessary for proliferation and cell cycle progression of MB cells.  
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Figure 17: Loss of Survivin causes decreased proliferation and cell cycle 
arrest. 
 (A-B) Cells were isolated from Survivinfl/fl;Ptch+/- tumors and infected with Cre- or 
GFP retroviruses for 48 hr. (A) GFP+ cells were isolated by flow cytometry and 
survivin mRNA expression analyzed by qRT-PCR (n=2). Cre causes loss of 
survivin expression (p<0.02). (B) Cells were pulsed with 3H-thymidine for 12 hr, 
harvested, and analyzed for incorporation. Loss of survivin leads to decreased 
tumor cell proliferation (p<0.001). Data are representative of 5 experiments. (C) 
Cells were isolated from Ptch+/- tumor (wild type for survivin), infected with Cre- or 
GFP viruses for 48 hr, and collected after 12 hr pulse with 3H-thymidine to 
measure incorporation. Infection with Cre virus alone does not significantly impair 
proliferation (p>0.1).  Data in (A-C) represent mean +/-  standard deviation (SD) 
and are representative of 4 experiments. (D, E) Cells from Survivinfl/fl;Ptch+/- 
tumors were infected with virus as described above (D. GFP, E. Cre virus) and 
stained with 7-AAD for cell cycle analysis by flow cytometry. survivin deletion 
causes accumulation of cells in G2/M. Data are representative of 4 experiments 
and cell cycle percentages based on live cell gates (excluded subG1). p values 
calculated using student’s t-test. 
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Figure 18: Survivin deletion inhibits proliferation of GNPs. 
(A-C) GNPs were isolated from P7 wildtype cerebella and infected with Cre or GFP 
expressing viruses for 48hrs. (A) Cells were pulsed with 3H-thymidine for 12 hr, 
harvested, and analyzed for incorporation. Loss of survivin leads to decreased 
GNP proliferation (p<0.001). (B-C) Infected GNPs  were analyzed for survivin 
deletion by PCR (B) and western blotting (C). survivin is deleted in GNPs following 
Cre infection. (C) Error bars are +/-SD and data are representative of 2 
experiments. 
 
3.2.3 Survivin antagonists inhibit MB cell proliferation and promote 
apoptosis 
Given the importance of Survivin for MB proliferation, we hypothesized that 
pharmacological agents that inhibit Survivin expression or function might interfere with 
tumor growth. To test this, we obtained several small molecule Survivin antagonists: 
YM155 is an inhibitor of survivin transcription229, whereas S12 and LLP3 bind directly to 
Survivin protein and interfere with its function230,231. To test the ability of YM155 to inhibit 
survivin expression in Ptch mutant MB cells, we treated cells with the drug for 48hrs, 
isolated RNA and performed qRT-PCR for survivin. YM155 markedly decreased survivin 
expression even at a concentration of 10 nM (Figure 19A). Similarly, loss of Survivin was 
detected at the protein level using western blotting (Figure 19B). These data suggest 
that YM155 effectively inhibits survivin expression in Ptch mutant MB cells. 
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Figure 19: YM155 inhibits survivin expression in MB cells. 
Ptch mutant tumor cells were treated with DMSO (D) or YM155 (Y) for 48 hours and 
analyzed for expression of survivin by real time PCR (A) and by western blotting 
after 24 hr. (B) YM155 dose in (B) is 1µM. YM155 decreases Survivin expression at 
both the RNA and protein level. Data are representative of 3 experiments.   
 
 To test the effects of Survivin antagonists on MB growth, we treated tumor cells 
with these agents and analyzed the percentage of cells expressing the proliferation 
marker Ki67. Consistent with our genetic results, inhibition of Survivin using either 
YM155 or S12 caused a significant decrease in the number of Ki67+ cells compared to 
treatment with vehicle (DMSO) (Figure 20A-D).  Additionally, we saw a dose dependent 
decrease in thymidine incorporation after treatment with YM155, S12, or LLP3 (Figure 
20E-F and Figure 22A). These data suggest that Survivin antagonists effectively inhibit 
MB growth in vitro. 
To determine whether Survivin antagonists also cause cell cycle arrest in MB 
cells, we performed cell cycle analysis. After 24hrs, cells treated with S12 showed a 
significant accumulation in G2/M (56%) compared to cells treated with vehicle (12%) 
(Figure 21A,C). G2/M accumulation was also seen at 36h (52%) (Figure 21B,D).  In 
contrast to S12, treatment with YM155 decreased the percentage of cells in G2/M (7%), 
with a concomitant increase in S phase (from 15 to 20% at 24hr) (Figure 21E-H). 
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Notwithstanding these differences, our data demonstrate that both Survivin antagonists 
alter normal cell cycle progression of MB cells. 
 
Figure 20: Survivin antagonists inhibit proliferation. 
(A-D) Tumor cells were plated on chamber slides and treated for 24 hr with control 
media (A), 0.1% DMSO (B), 10 µg/ml S12 (C), or 50 nM YM155 (D). Cells were 
stained with anti-Ki67 antibodies (green) to mark proliferating cells and DAPI 
(blue) to label cell nuclei. Very few cells were Ki67+ after treatment with Survivin 
antagonists compared to controls (p<0.0001 for YM155 and S12). Data are 
representative of 3 experiments. (E-F) Ptch mutant tumor cells were treated with 
multiple doses of YM155 (E) or S12 (F) for 48 hr and pulsed with 3H-thymidine for 
12 hr to measure proliferation. Treatment with either antagonist decreased 
proliferation in a dose-dependent manner (p< 0.02 for all YM155 and S12 doses 
except 5µg/ml S12, which was not significant (NS)).  Ki67+ percentages in (A) were 
averaged from 6 images for each treatment. Data in (E-F) represent mean +/- SD 
and are representative of 6 experiments. Stats were calculated by ANOVA and 
post hoc student’s t-tests. 
 
In addition to its role in regulating cell cycle progression, Survivin has been 
suggested to function as an inhibitor of apoptosis. To determine if Survivin inhibition 
promotes MB cell apoptosis, tumor cells were treated with Survivin antagonists and then 
stained with Annexin-V and propidium iodide (PI). As shown in Figure 21E-G, 
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antagonists increased the percentage of apoptotic (AnnexinV+) tumor cells from 21% 
(after DMSO treatment) to 62% (S12) or 59% (YM155). Similarly, LLP3 treatment 
increased the percentage of Annexin+ and PI+ cells (Figure 22B-E). These data show 
that Survivin antagonists are not merely cytostatic, but can promote apoptosis of tumor 
cells as well.  
 
Figure 21: Survivin antagonists alter cell cycle progression and promote 
apoptosis. 
(A-H) Ptch mutant tumor cells were treated with either DMSO (A,B,E,F), 20 µg/ml 
S12 (C,D), or 100 nM YM155 (G,H) and stained with 7-AAD for cell cycle analysis 
after 24 hr (A,C,E,G) or 36 hr (B,D,F,H). YM155 decreased the percentage of cells in 
G2/M, while S12 treatment caused an accumulation of cells in G2/M. Data 
represent 4 (A-D) and 6 (E-H) experiments and percentages based on live cell 
gates (excluded subG1). (I-K) Tumor cells were treated with DMSO (I), 20 µg/ml (J), 
or 100nM YM155 (K) for 36 hr, then collected and stained with Propidium Iodide 
(PI) and Annexin-V for FACS analysis. The percentage of apoptotic cells was 
significantly higher after antagonist treatment compared to control. Data 
represent 6 independent experiments. 
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Figure 22: LLP3 inhibits proliferation and causes cell death of Ptch mutant 
tumor cells. 
A) Ptch mutant tumor cells were treated with DMSO  or multiple doses of LLP3 for 
48 hr and pulsed with 3H-thymidine for 12 hr to measure proliferation. Treatment 
decreased proliferation in a dose-dependent manner (p<0.05 by ANOVA with post 
hoc student’s ttest). Data represent mean +/- SD and are representative of 3 
experiments. (B-E)Tumor cells were treated with DMSO (B), 2 µM (C), 4 µM (D), or 
10 µM LLP3 (E) for 36 hr, then collected and stained with Propidium Iodide (PI) and 
Annexin-V for FACS analysis. The percentage of Annexin and PI+ cells was 
increased after treatment with LLP3. Data are representative of three experiments. 
 
To verify that Survivin antagonists were not inducing non-specific toxicity, we 
tested their effects on GNPs, which express survivin (see Figure 16), and post-mitotic 
neurons, which do not.  Treatment of GNPs with YM155 or S12 caused a dose 
dependent increase in the percentage of dead cells (as measured by EthD1 staining). In 
contrast, survival of post-mitotic neurons was not affected by treatment with Survivin 
antagonists (Fig 23A,B). These data suggest that Survivin antagonists induce death of 
Survivin-expressing cells but are not toxic to normal cerebellar neurons. 
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Figure 23: Survivin antagonists kill GNPs but not do not affect survival of 
post-mitotic neurons. 
Granule Neuron Precursors (GNPs) were isolated from P7 wild type cerebella, split 
into two treatment groups, and plated in either SHH-containing media (A) or 
differentiation media (B).  Cells in SHH-containing media were treated immediately 
with DMSO, YM155, or S12 for 48 hr and incubated with ethidium homodimer1 
(EthD1) to mark dead/dying cells (A). Cells in differentiation media were cultured 
for 5 days, followed by treatment with DMSO, YM155, or S12 for 48 hr and 
incubation with EthD1 to mark dead/dying cells (B). Both S12 and YM155 caused 
GNP cell death at high doses (p<0.01 for high doses. NS for 50nM YM155 and 
10µg/ml S12), but did not kill PMNs (P>0.2, NS for all doses). Data represent mean 
+/-  SD and are representative of 4 independent experiments. 
 
3.2.4 Survivin antagonists cooperate with radiation and SHH antagonists  
Among the major drawbacks of current MB therapy are the devastating side 
effects of radiation232,233. Since recent studies have suggested that YM155 can enhance 
the efficacy of radiotherapy against NSCLC234, we hypothesized that combining radiation 
and Survivin antagonists might be effective for MB as well. To test this, we performed 
thymidine incorporation assays on tumor cells treated with Survivin antagonists for 24hr 
followed by exposure to varying doses of radiation (Figure 24A). Treatment with sub-
optimal doses of YM155 and S12 alone resulted in a small decrease in proliferation. The 
combination of Survivin antagonists and 0.25 grey (Gy) radiation markedly decreased  
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Figure 24: Survivin antagonists cooperate with radiation and LDE225 SHH 
antagonists. 
A) Tumor cells were treated with either 0.1% DMSO, 50 nM YM155, or 10 µg/ml S12 
for 24 hr, and then irradiated with 0, 0.25, or 0.5 gray (Gy). After 24 hr, cells were 
pulsed with 3H-thymidine and assayed for incorporation. Treatment with 
antagonists enhanced sensitivity of tumor cells to radiation (p<0.02 for all 
treatments, calculated by 2 way ANOVA to identify radiation dose by treatment 
interaction, split by radiation dose, with post hoc student’s t-tests) Data are 
representative of 5 experiments. (B,C) Tumor cells were plated in 96 well plates 
and treated with LDE225 alone (at the indicated concentrations) or in combination 
with 20 nM YM155 (B) or 10 µg/ml S12 (C). Cells were pulsed with 3H-thymidine 
after 48 hr and harvested to assay levels of incorporation. Combination treatment 
of LDE with either S12 or YM155 significantly lowered the IC50 compared to LDE 
alone (p< 0.01 by student’s t-test). Data are representative of 4  (B) and 3 (C) 
experiments. All data represent mean +/- SD. 
 
tumor cell proliferation compared to radiation alone. The level of inhibition achieved with 
the combination treatment was equivalent to that achieved by doubling the radiation 
dose.  These data suggest that Survivin antagonists can enhance the effects of radiation 
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on MB cells, and raise the possibility that these agents might allow reduction in the 
doses of radiation used for therapy. 
In addition to conventional therapy, targeted therapies have begun to be 
evaluated for treatment MB. For SHH-associated tumors, NVP-LDE225 a small molecule 
antagonist of SMO, has shown some efficacy in animal models as well as in 
patients21,235. To test whether Survivin antagonists increase the efficacy of SHH 
antagonists, we treated Ptch mutant tumor cells with various concentrations of LDE225 
alone or in combination with 10µg/ml S12 (Figure 5B). LDE225 alone had an IC50 of 5.5 
nM (range: 3-8.5 nM) while the combination of LDE225 and S12 markedly decreased the 
IC50 to 0.04 nM (range: 0.04-2 nM). Similarly, exposure to 20 nM YM155 decreased the 
IC50 of LDE225 (from 13.5nM to 6.4nM). These data suggest that Survivin antagonists 
significantly enhance growth inhibition by SHH antagonists.  
3.2.5 Survivin antagonists inhibit growth of human SHH-driven MB cells 
The studies described above focused on murine SHH-associated MB. To 
determine whether human SHH-driven MB cells also respond to Survivin antagonists, 
we used patient-derived xenografts (PDXs) from SHH-driven tumors. Treatment of PDX 
cells with Survivin antagonists in vitro led to significant decreases in 3H-thymidine 
incorporation (Figure 25A-C). Tumor cells were also treated with the SMO antagonist 
LDE225. Notably, the PDX line with a mutation upstream of SMO (DMB-012) was 
responsive to LDE225 145,236 whereas the lines with mutations downstream of SMO 
(RCMB-018 and ICb-984MB) were resistant (Figure 25B,C, 237 and data not shown). In 
contrast, all three lines responded robustly to YM155 and high dose S12. These data 
suggest that Survivin antagonists can inhibit the growth of human SHH-driven MBs and 
that they may be useful for treating tumors that are resistant to SMO antagonists. 
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Figure 25: Survivin antagonists inhibit proliferation of human SHH-driven 
MB cells. 
Cells isolated from LDE225-sensitive xenograft DMB012 (A) and LDE-insensitive 
xenografts RCMB018 (B) and ICb-984MB  (C) were treated for 48 hr with DMSO, 
LDE225, YM155 or S12, and analyzed for thymidine incorporation following a 12-16 
hr pulse.  All tumor cells were sensitive to YM155 inhibition and high dose S12 
treatment (DMB012 p<0.01 for all doses, RCM018 and ICb-984MB p<0.03 for YM155 
and 10µg/ml S12 while LDE and 20µg/ml S12 were not significant with p>0.08). All 
stats were calculated by ANOVA and post hoc student’s t-test. Data represent 
mean +/- SD and are representative of 3 experiments. 
 
3.2.6 Non-SHH driven MB cells are also sensitive to Survivin inhibition 
Seeing the efficacy of survivin antagonists against both LDE-responsive and 
resistance SHH driven tumors, we were interested to explore whether they may inhibit 
the growth of other subtypes of MB as well. Previous studies in our lab on a mouse 
model of Group 3 MB driven by Myc overexpression demonstrated that Survivin is highly 
expressed in these tumors compared to normal stem cells (the normal cell of origin for 
these tumors)80.  Additionally, analysis of publically available databases of human MB 
gene expression revealed that BIRC5 is expressed in all 4 subtypes (Figure 26A). So 
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Survivin could be a viable target for these tumors. Treatment of either murine (MP)80 or 
PDX group 3 MB cells with Survivin antagonists impeded proliferation as measured by 
3H-thymidine incorporation (Figure B-C). Finally, Group 4 PDX cells were also sensitive 
to Survivin inhibition by YM155 (Figure D). These data suggest that Survivin antagonists 
may be more broadly applicable for treatment of multiple subtypes of MB. 
 
Figure 26: Non-SHH tumors express survivin respond to Survivin 
antagonists. 
(A) R2 data from Northcott dataset was analyzed for survivin expression. All 
subtypes of human MB express survivin.(B-D) Cells were isolated from murine MP 
tumors (B), MB002 (group 3) xenograft (C), or ICb-1299 (Group 4) xenograft and 
treated with DMSO, YM155, or S12 (only C and D) for 48hrs. YM155 inhibits 
proliferation of both murine and human tumor cells. Both Group3 and Group4 
tumors are sensitive to inhibition by S12 as well. (Murine MP, p<0.001, MB002, 
p<0.02 except for 20 µg/ml S12 which was NS, ICb-1299MB p<0.003 for all 
treatments). All stats were calculated using ANOVA and post hoc student’s ttest. 
Data represent mean +/- SD and data from panels B-D are representative of two 
group tumors each.  
 
3.2.7 Requirement of survivin for tumor initiation and maintenance 
So far, both our genetic and pharmacological, have demonstrated the importance 
of Survivin for growth and survival of tumor cells in vitro. We were further interested in 
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the role of survivin in vivo. To test the importance of Survivin for tumor initiation, we used 
a genetic approach to delete Survivin at early stages of tumor formation. To this end, we 
crossed Math1Cre;Ptchfl/fl mice and Survivinfl/fl  mice to generate the MCSP mice, in 
which survivin is deleted concurrently with Ptch in GNPs. We and others have previously 
used the Math1Cre;Ptchfl/fl mice to generate hedgehog-driven medulloblastoma79,115.  
These mice develop tumors with 100% penetrance and short latency of 6-12 weeks115. 
Although initially there seemed to be a delay in tumor latency when survivin is deleted, 
the survival curve shown in Figure 27 demonstrates that loss of survivin does not impair 
the ability of tumors to develop in vivo.  
 
Figure 27: In vivo deletion of survivin may not inhibit tumor formation.  
(A) Survival curve of Math1Cre; SurvivinWT, Survivinfl/+, and Survivinfl/fl mice. All 
mice develop tumors with similar latency.(B-D) Tumors from SurvivinWT (B) and 
Survivinfl/fl (C,D) mice were stained with anti-survivin antibodies. All tumors 
displayed significant survivin staining (abrogated by blocking peptide (D)). Scale 
bars represent 100µM.  
Staining of the resulting tumors with anti-survivin antibodies revealed that all 
tumors expressed Survivin, regardless of genotype (SurvivinWT, Survivinfl/+(not shown), 
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or Survivinfl/fl, Figure 27B-D). These data suggest that Survivin is either not required for 
tumor initiation, or more likely that tumors were able to form from cells that still express 
survivin due to insufficient deletion. Evaluation of survivin deletion in normal P8 GNPs 
(using Math1CreER; Survivinfl/fl mice, Figure 28A) or deletion embryonically in 
Math1Cre;Survivinfl/fl mice (Figure 28B-G) demonstrated that while there is some 
deletion of survivin in vivo, it may not be very efficient.  This was surprising, as Math1Cre 
has been used to efficiently delete other genes in GNPs24,115. 
 
Figure 28: In vivo survivin deletion in GNPs is not efficient.  
(A) Math1CreER; SurvivinWT, Survivinfl/+, and Survivinfl/fl mice were treated with 
tamoxifen at P4. Protein was isolated from P7 GNPs and survivin expression was 
analyzed by western blotting. Survivinfl/+ and Survivinfl/fl cells displayed incomplete 
deletion, with slightly lower levels of Survivin than wildtype littermates. These 
data are representative of 4 experiments. (B,C) Cerebella from P7 
Math1Cre;SurvivinWT (B) and Math1Cre; Survivinfl/fl  (C) were stained with anti-
survivin antibodies to evaluate Survivin expression. Both SurvivinWT and 
Survivinfl/fl mice express survivin in the EGL (where GNPs reside). Scale bars 
represent 50µM and data represent 2 experiments with 2 animals per condition.  
(D-G) Cerebella from E16.5 Math1Cre;SurvivinWT(D,E) and Math1Cre;Survivinfl/fl 
(F,G) were stained with anti-Ki67 antibodies to mark proliferating cells (E,G) and 
Dapi to mark cell nuclei (D,F). SurvivinWT and Survivinfl/fl cerebella display similar 
proliferation in the ventricular zone and EGL.  
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To analyze the ability of survivin deleted cells to form tumors in vivo, cells from 
SP mice were infected with Cre-IRES-GFP expressing viruses and sorted for GFP 
expression to select for survivin deleted cells. Once collected, these cells were 
transplanted into cerebella of immunocompromised mice and monitored for survival. We 
have demonstrated previously that survivin is deleted efficiently using this approach (see 
Figures 17A and 18B,C). Preliminary studies suggested that loss of survivin impedes 
tumor formation (Figure 29A-E), but subsequent studies with either viral Cre-mediated 
deletion or tamoxifen induced deletion in tumor cells derived from  Survivinfl/fl; Math1-
Cre-ER; Ptc+/- (SMEP)  mice  were inconclusive due to variable tumor take after 
transplantation in controls (See Table 1).    
 
Figure 29: Preliminary Cre-mediated survivin deletion inhibits tumor 
formation. 
 SP tumor cells were infected for 36hrs with Cre or GFP expressing viruses, 
sorted, and GFP+ cells were transplanted into the cerebella of NSG mice. Whole 
mount (A,C) and GFP (B,D) images from control GFP-infected mice (A,B) and Cre 
infected mice (C,D).  GFP infected cells formed GFP+ tumors, Cre infected cells 
did not form a tumor. (E) Survival curve of mice implanted with uninfected, GFP+, 
and Cre+ SP tumor cells. Five mice were analyzed in initial experiment.  
 
Similarly, treatment of SMEP tumor-bearing NSGs  in vivo with tamoxifen to determine 
importance of survivin for tumor maintenance were equally variable and thus difficult to 
interpret (data not shown). Despite our technical challenges in establishing the role of 
 67 
survivin in in vivo tumors, it is possible that survivin is still critical for growth and 
maintenance of tumors and that targeting it would be effective.  
Table 1: Variability in tumor take following GFP+ and Cre+ SP tumor 
transplantation or in vitro tamoxifen treatment of SMEP tumors 
 
3.2.8 Survivin antagonists do not inhibit growth of intracranial tumors due 
to poor blood brain barrier penetration 
Given the ability of Survivin antagonists to inhibit proliferation and promote 
apoptosis of tumor cells in vitro, we questioned whether inhibiting Survivin could prevent 
tumor growth in vivo. To test this, MERP mice were treated with tamoxifen at P4 to 
delete Ptch and allowed to develop tumors for 3 months. Mice were then treated with 
YM155 or vehicle by microosmotic pump for 2 weeks and tumor volumes calculated. 
There was no detectable difference in tumor size between treated and control mice 
(Figure 30A-C), due in part to the large variability in starting tumor size between mice. 
Previous studies have shown that there is a spread in tumor latency from 12-19 weeks in 
these animals115, so it is perhaps not surprising that within the cohort of mice there was a 
range of small and large tumors that obscured results.  
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Figure 30: YM155 doe not inhibit the growth of endogenous Ptch mutant 
medulloblastomas. 
Three month old MERP mice (tamoxifen treated at P4 to delete Ptch) were 
implanted with microosmotic pumps containing saline control (n=4), 3mg/kg 
YM155(n=3), or 5mg/kg (n=3) YM155 and treated for 2 weeks. Tumors from vehicle 
(A) and YM155 (B) treated mice were H&E stained and tumor volumes were 
calculated (C). Green boundaries indicate tumor areas counted. Tumors in both 
the vehicle and YM155 treated groups were variable in size. 
 
To overcome the variability in tumor size encountered with endogenous tumors, 
Ptch tumor cells were isolated, infected with luciferase expressing viruses, and 
transplanted into the cerebella of NSG mice for treatment. Mice were grouped based on 
bioluminescence signal (as a surrogate for tumor size) and treated with either 
5mg/kg/day YM155 (Figure 31A), 15mg/kg S12 (Figure 31B), or vehicle control. As can 
be seen in Figure 31, neither treatment resulted in significantly prolonged survival 
compared to vehicle treated controls, suggesting that our antagonists do not inhibit the 
growth of intracranial tumors. This was surprising, given the potency of these 
compounds in vitro. 
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Figure 31: Survivin antagonists do not inhibit intracranial tumor growth. 
Ptch mutant tumor cells were infected with luciferase expressing viruses 
overnight and transplanted into the cerebella of NSG mice. Mice were placed into 
treatment groups based on luciferase signal and treatment commenced after one 
month. (A)  Mice were treated for 28days with 5mg/kg/day YM155 or saline control 
via microosmotic pump and monitored for survival.(n=6  YM155, n=5 vehicle) (B) 
Mice were treated with 15mg/kg S12 or vehicle 5x a week by i.p. injection and 
monitored for survival (n=5 YM155, n=4 DMSO). Neither YM155 or S12 were able to 
prolong survival. These data are representative of two experiments. 
 
A possible explanation is inability of these molecules to cross the blood brain 
barrier (BBB), a major obstacle for many potential CNS therapeutics238. To address this, 
we collaborated with the SBMRI Exploratory Pharmacology Core to perform an in vitro 
parallel artificial membrane permeability assay (PAMPA) assay to mimic BBB 
penetration. While LDE-225 was shown to be highly brain permeant, as expected, this 
assay demonstrated quite clearly that YM155 was unlikely to cross the BBB (Table 2). 
Indeed, a recent study from Minematsu et al. has demonstrated YM155 does not 
accumulate in the brain to any appreciable degree239. S12 on the other hand would be 
predicted to be able to cross at least moderately well (Table 2). 
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Table 2: In vitro blood brain barrier permeability of survivin antagonists 
 
Despite the prediction that S12 should be able to cross the BBB, we did not see 
in vivo efficacy with S12. To address whether S12 accumulates at high enough levels in 
vivo to inhibit tumor growth, we performed pharmacokinetic studies in collaboration with 
the core at Sanford Burnham in Lake Nona. SCID/Beige mice were implanted with Ptch 
mutant tumors and tumors were allowed to develop for 5-6 weeks. Mice were then 
treated with a single dose of S12 (15 mg/kg) and plasma, normal brain, and tumor were 
harvested after either 30 mins or 2 hours. As can be seen in Table 3, while S12 does get 
in to the brain and tumor tissue to some degree initially (highest concentration in tumor 
was 1.1 µg/ml at 30mins), the antagonist is quickly cleared from the tumor tissue 
(average 0.163µg/ml). These levels do not even approach the in vitro IC50 for S12 ( ~10 
µg/ml, see Figure 20F), so clearly the necessary levels of S12 are not being achieved in 
intracranial tumors.  Similar rapid clearance was observed in the plasma of treated mice. 
Interestingly, normal brain tissue continued to accumulate S12 between 30 mins and 2 
hours after treatment, although levels were also relatively low. These data together 
suggest that our antagonists do not accumulate in intracranial tumors enough to inhibit 
growth. 
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Table 3: PK of S12  
 
*N=3 mice for each timepoint 
3.2.9 Survivin antagonists inhibit the growth of MB flank xenografts 
Given that published reports ( see Ref 239) as well as our own preliminary 
studies suggested that our Survivin antagonists do not accumulate in the brain 
or intracranial tumors sufficiently, we moved to a flank tumor model to test the ability of 
the antagonists to inhibit tumor growth in vivo. Ptch mutant tumors were implanted into 
the flanks of Nu/Nu mice and treated with YM155 or vehicle. Intratumoral injections of 
YM155 significantly decreased tumor growth compared to treatment with vehicle 
(Fig7A). Tumors harvested after 6 weeks of treatment were much smaller than those in 
the vehicle treated mice (Fig7B, C). We also tested whether systemic treatment with 
YM155 could inhibit tumor growth in vivo; since YM155 has a short half-life, we used 
osmotic pumps for delivery216,229,240. Nu/Nu mice bearing Ptch mutant flank tumors were 
implanted with micro-osmotic pumps to continuously infuse YM155 or vehicle (saline) for 
3 weeks.  Tumors in mice with YM155-containing pumps grew significantly less than 
those in mice with vehicle pumps (Fig 7D-F).  These data suggest that Survivin 
antagonists can potently inhibit MB growth in vivo. 
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Figure 32: YM155 inhibits growth of Ptch mutant tumor cells in vivo. 
(A-F) Tumor cells were suspended in GFR matrigel (1:1 with media) and implanted 
in the flanks of Nude mice. When tumors reached ~100mm3, mice were split into 
two cohorts and treatment was started. For (A-C), tumors were treated with 
vehicle (20% DMSO in saline) or YM155 (20 µM) via intratumoral injection twice a 
week (vehicle n=5, YM155 n=6).  For (D-F), mice were treated with vehicle (saline) 
or YM155 (10 mg/kg/day) via micro-osmotic pump (vehicle n=6, YM155 n=5). 
Caliper measurements were made twice a week to monitor tumor growth (A,D) and 
resulting tumors were collected, photographed (B,E), and weighed (C,F). 
Experiments were repeated 2 (A-C) and 3 times (D-F) respectively. Both intra-
tumoral and systemic treatment with YM155 decreased tumor size over time 
compared to vehicle control. (p<0.02 for IT and pump YM155 tumor weight by 
ANOVA with post hoc student’s t-test). Error bars represent SEM.  
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3.3. Discussion 
Previous studies have shown that Survivin is expressed in human MB, and that 
its expression is correlated with poor outcome. To study the role of Survivin in MB 
growth and survival, we used a mouse model of MB driven by activation of the SHH 
pathway. Our studies demonstrate that Survivin is highly expressed in SHH-driven MB 
and that genetic and pharmacologic inhibition of Survivin impedes growth of MB cells in 
vitro and in vivo. 
Our initial studies demonstrated that Survivin is expressed at high levels in Ptch 
mutant MB cells and not in normal adult cerebellum, suggesting that it might represent a 
cancer-selective target.  To test the functional importance of Survivin in MB cells, we 
used Cre viruses to delete Survivin from Survivinf/flx;Ptch+/- tumor cells. Loss of Survivin 
resulted in markedly decreased proliferation and caused arrest in the G2/M phases of 
the cell cycle. These results are consistent with the function of Survivin as a member of 
the chromosomal passenger complex, which is critical for alignment of chromosomes 
during metaphase and for successful cell cleavage164,167. In addition, previous studies 
have shown that loss of Survivin leads to aberrant mitosis, centrosome amplification and 
failed cytokinesis in a number of cancers, including glioma and cervical cancer173,241. 
Thus, in MB as in other tumors, Survivin seems to be critical for normal proliferation and 
cell cycle progression.  
To evaluate Survivin’s utility as a therapeutic target, we used small molecule 
antagonists. Consistent with our genetic studies, Survivin antagonists significantly 
decreased proliferation and altered cell cycle progression. Interestingly, while S12 
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treatment caused accumulation of cells in G2/M phase (similar to survivin deletion), 
YM155 caused cells to accumulate in S-phase. This observation is consistent with 
previous studies that demonstrated YM155 treatment can cause a loss of new DNA 
synthesis and concomitant stall in S phase242. This discrepancy between S12 and 
YM155 could be due to differences in the kinetics or degree of Survivin inhibition 
induced by these drugs. Alternatively, it could result from differences in the mechanisms 
by which the drugs act: whereas S12 binds directly to Survivin protein230, YM155 inhibits 
survivin expression by disrupting ILF3/NF110 complexes243,244 or Sp1 binding245 at the 
survivin promoter. Thus, in addition to potently decreasing survivin expression (see Ref 
229
 and Figure 19), YM155 may also alter expression of other genes that regulate cell 
cycle progression (e.g. cyclin D1, p27) 246,247, and thereby cause arrest at earlier stages 
of the cycle. In other words, YM155 may function as a broader inhibitor of cell cycle than 
other Survivin antagonists. Nonetheless, the fact that genetic deletion and several small 
molecule inhibitors all interfere with cell cycle progression in Ptch mutant tumor cells 
strongly supports the notion that Survivin is required for this process in SHH-driven MB. 
In addition to their effects on the cell cycle, Survivin antagonists also increased 
the percentage of MB cells undergoing apoptosis. It remains unclear whether loss of 
Survivin function causes apoptosis directly or as a consequence of cell cycle arrest. 
Analysis of Annexin+ cells after treatment with Survivin antagonists showed that 
apoptosis is not detectable until 36hr, whereas cell cycle inhibition is observed by 12-
24hr. These results are consistent with the notion that apoptosis occurs secondary to 
cell cycle arrest. The fact that Survivin antagonists not only inhibit proliferation but also 
cause death of tumor cells may make them potent therapeutic agents for MB.   
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Importantly, we demonstrate that Survivin antagonists do not display non-specific 
neuronal toxicity, suggesting that they may be safe to use in the clinic. Additionally, our 
data show that higher doses of these drugs are required to inhibit the proliferation of 
survivin-expressing precursors in the cerebellum than are needed to interfere with tumor 
growth. This indicates that there could be a good therapeutic window for use of these 
drugs. This is important to establish, since recent studies have demonstrated that 
survivin has a role in some restricted adult tissues, including T lymphocytes, 
hematopoietic progenitors, and endothelial cells157. Despite this, early stage clinical trial 
data with YM155 and other survivin targeting methods support the safety of these 
approaches, as minimal toxicity was observed and most the serious symptoms observed 
(nephrotoxicity) were completely reversible218,219,248. Together these observations 
suggest that Survivin antagonists may be a safe and effective way to treat MB patients. 
Previous studies of glioma and other cancers have suggested that targeting 
Survivin can enhance the effects of radiation and chemotherapy186,216,234,249-253. In 
agreement with these data, we found that Survivin antagonists significantly enhanced 
the sensitivity of MB cells to radiation. Combining low dose radiation (0.25 grey) with 
S12 or YM155 was as effective at inhibiting tumor growth as doubling the dose of 
radiation. These data suggest that addition of Survivin antagonists may allow children to 
be treated with lower doses of radiation without decreasing therapeutic benefits. The 
approach could markedly reduce treatment-related side effects and improve the long 
term quality of life of MB patients.  
A major advance in treatment of SHH driven MB has been the development of 
SMO antagonists. However, one drawback of these agents is the swift acquisition of 
resistance to the drug and tumor recurrence. Our studies show that combining LDE225 
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and Survivin antagonists significantly enhanced inhibition of proliferation compared to 
either drug alone. Although in these studies we focused on co-treatment, it would be 
interesting to look at the ability of Survivin antagonists to overcome LDE225 resistance. 
In this context, it is notable that in non-small cell lung cancer, downregulation of Survivin 
by either siRNA or treatment with YM155 reverses Erlotinib resistance254. It is also 
important to note that LDE225 and other SHH antagonists work at the level of SMO, and 
are thus ineffective for patients with mutations downstream in the SHH pathway145. We 
show that human PDX cells with such downstream mutations are still sensitive to 
inhibition by Survivin antagonists. This suggests that treatment with Survivin antagonists 
could potentially compliment current targeted therapies to enhance response. In 
addition, our preliminary studies suggest that that YM155 can inhibit growth of non-SHH-
associated MB cells, both murine and human. Although questions remain about the 
specificity of YM155 for Survivin, these studies raise the possibility that Survivin may be 
a therapeutic target for a broad spectrum of MB patients.  
Numerous studies suggest a role for Survivin tumor formation and progression. 
Increased expression of survivin in preneoplastic lesions in colon cancer255,256,  prostatic 
intraepithelial neoplasia257, and preliminary studies from our lab in MB (data not shown) 
suggests up-regulation of survivin is an early event in malignant transformation.  A 
recent study in liver cancer showed elevated survivin expression in dysplastic liver 
nodules and further that Survivin activity is critical for cell survival during tumor 
initiation207. Additionally, Survivin expression is important for tumor progression from 
prostatic intraepithelial neoplasia to adenocarcinoma206. Consistent with these findings, 
elevated expression is correlated with increasing tumor grade in numerous cancers, 
including colorectal cancer258. Genetic deletion studies aimed at evaluating the 
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importance of survivin for MB tumor initiation revealed that tumors still form in Survivinfl/fl 
animals and furthermore that resultant tumors express high levels of Survivin. This could 
indicate incomplete deletion of survivin in precursor cells and a strong selective pressure 
for those cells that maintain survivin expression. It is possible that cells without Survivin 
stop proliferating and/or undergo apoptosis and tumors form from the remaining Survivin 
wildtype cells.  Although we have observed efficient deletion of Survivin in vitro by either 
virally- expressed Cre or tamoxifen treatment (See Figure 18 and data not shown), initial 
in vivo studies in GNPs and tumors have suggested deletion may not be as efficient 
under the Math1 enhancer in vivo. Additionally, the broad window of tumor latency for 
SurvivinWT mice in combination with the relatively small number of tumors we obtained in 
these studies may also have obscured any differences in latency that would have arisen 
in a larger dataset. The fact that all tumors still expressed Survivin suggests that it could 
still be important for tumor initiation or growth and warrants further study.   
Lastly, we have shown that YM155 can inhibit tumor growth in vivo, either by 
direct intratumoral injection or systemic administration. These data strongly suggest that 
targeting Survivin could be an effective approach for treating MB. A major challenge in 
treatment of brain tumors is the ability of drugs to cross the blood brain barrier (BBB). 
The BBB, which consists of capillary endothelial cells joined by tight junctions and 
surrounded by a thick basement membrane and astrocytic endfeet259,260, strictly 
regulates the entrance of the majority of small molecules into the central nervous 
system261. Additionally, many drugs that do manage to cross the barrier are substrates 
for multi-drug transporters (MDTs), which pump them out of the brain262-264. Because of 
this, even compounds that potently inhibit tumor growth in vitro may not reach high 
enough concentrations in the brain to achieve therapeutic effects. Unfortunately, 
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pharmacokinetic studies by our lab and others239 suggest that the Survivin antagonists 
we have tested do not show significant accumulation in the brain or in intracranial 
tumors. Additionally, in vitro studies by Iwai et al. suggested that YM155 may be a 
substrate for P-glycoprotein MDR1265, a ATP family transporter that is known to be a 
critical regulator of BBB permeability to drugs266,267. Thus, chemical modification of these 
agents, or alternative modes of delivery may be necessary to make these agents useful 
for treatment of MB and other brain tumors.  
Although our experiments combining Survivin antagonists with adenosine 
agonists to facilitate BBB penetration were not successful (data not shown), other 
treatments modalities aimed at disrupting the barrier may prove more beneficial. Since 
studies have suggested YM155 is substrate for MDTs, co-administration with an MDT 
inhibitor such as Elacridar, which has been safely used in clinical trials268 could be 
pursued. Another paradigm that has recently emerged in the preclinicial studies for 
treatment of glioma is disruption of the barrier using focused ultrasound with intravenous 
microbubble injection269. This approach has been used to deliver chemotherapeutics270-
274
 , stem and immune cells275,276, and even antibodies277-279 into the brain, and disruption 
was shown to be focal, reversible, and safe280-282. Also, a recent study has suggested 
that treatment with hedgehog antagonists such as LDE255 could facilitate delivery of 
other molecules to the brain through disruption of the barrier itself283. Treatment in vivo 
with this combination may be particularly effective due to both the cooperation of these 
particular drugs (as our studies in vitro showed) and enhanced delivery of Survivin 
antagonists to the tumor. This would be a promising avenue for future exploration. 
Other methods of delivery don’t impair the barrier itself, but instead circumvent it 
to get drugs to the tumors. Global disruption of the barrier could have severe 
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consequences, as the barrier is essential for protecting neurons from systemic toxins 
and maintaining proper homeostasis284. More targeted strategies would therefore be 
preferable. One possible clinically available method to enhance delivery to the brain is to 
use convection-enhanced delivery (CED). This approach involves implantation of 
catheter(s) directly into the tumor mass or resected tumor bed for local delivery, 
bypassing the BBB285. Clinical trials have shown successful delivery of both cytotoxins 
and antibodies for treatment of glioma using CED 286,287.  Intrathecal delivery (delivery 
directly into the cerebro-spinal fluid via catheter in the spine), is another viable clinical 
option for delivery of Survivin antagonists. It is commonly used to deliver analegesics for 
management of both cancer and non-cancer related pain when more conservative 
therapies fail288. Additionally, it has been explored in clinical trials as an avenue for 
delivery of antibodies for treatment of brain tumors289,290. Other more preclinical avenues 
such as nanoparticle- (or stem cell -) mediated delivery could also be evaluated. 
Numerous studies have demonstrated the ability of drug loaded nanoparticles to home 
to tumors291 and BBB penetrable nanoparticles have recently been developed292. 
Given the potency of survivin antagonists in vitro and effects of YM155 as a 
single agent on flank tumor growth, targeting Survivin in MB is a very promising strategy 
for treatment of this disease. Pursuing new methods of delivery will be a critical next step 
to moving these therapies forward to treating patients with MB. 
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4. Discussion 
In these studies, we have used mouse models to study early stages of tumor 
development and test a novel therapeutic target for treatment of medulloblastoma. Some 
major questions and concepts that we consider in this remaining chapter are:  1) utility of 
mouse models for preclinical testing, 2) importance of defining and studying the cell of 
origin, 3) implications of Wnt pathway activation for novel therapies, 4) relevance of 
mitotic inhibitors as cancer therapy, 5) overcoming resistance using Survivin 
antagonists, and 6) considerations of the blood-tumor barrier in development of novel 
therapies for MB 
4.1 Mice as models for human disease 
In Chapters 2 and 3, we utilize mouse models to study the role of WNT signaling 
in cells of the developing cerebellum and to evaluate the efficacy of survivin antagonists 
to treat Shh-driven MB. Proof of efficacy and safety in animal models is a major criterion 
for moving drugs forward into clinical trials. Despite the weight these studies carry, a 
dismal proportion of compounds that look promising in mice translate to efficacy in the 
clinic91,293. These failures to predict efficacy stem from numerous factors. The major 
(obvious) fact is that mice are not people. There are differences in how drugs are 
distributed through the body and how they are metabolized. Differences in underlying 
genetics of mice are a huge factor as well. Even if mouse models are driven by similar 
mutations as found in human cells, there are species-specific differences in the role of 
genes in different cell types which can lead to presentation of different phenotypes and 
altered response to therapy294. The ability to predict is tied to how closely models reflect 
the complexity of human disease in terms of genetics, tumor cell composition, 
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microenvironment interactions, and response to therapy and often, models recapitulate 
only certain aspects of the disease.  
Beyond the inherent differences between rodent models and humans, many 
times faults in study design lead to inaccurate conclusions about compound efficacy295. 
There is no standard for how preclinical studies are carried out and frequently they are 
not designed with sufficient numbers and clinically relevant endpoints295.  In a telling 
study by Perrin et al, compounds that were previously reported to slow down 
progression of amyotrophic lateral sclerosis but failed in human trials were subjected to 
testing using more rigorous guidelines (in the same models). Interestingly, all of the 
drugs were not efficacious in the re-tests and more closely resembled the human 
studies296. Additionally, failure in clinical trials can also be caused by incorrect patient 
selection. For example, SHH antagonists are not efficacious in MBs that are not driven 
by hedgehog pathway activation236. These compounds would therefore fail in trials that 
did not take into account MB subtypes and assign patients accordingly. Many promising 
therapeutics can be rejected for lack of effect because the relevant patient subpopulation 
has not been identified.    
It is also important to note that majority of reports claiming poor correlation of 
efficacy between mouse and human trials are based on analysis of models of human cell 
line xenografts that may not be very representative of endogenous human tumor growth 
and response. After long term selection in culture, the cell lines have lost many of 
features of the original tumors and certainly no longer reflect the clonal heterogeneity of 
human tumors297. Importantly, it is known that stromal and immune factors can influence 
tumor evolution and drug response. Tumors from these models are grown in a foreign 
environment (commonly the flank) and are propagated in immuno-compromised 
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animals, eliminating the ability to model any of these critical interactions. Recent 
development and application of genetically engineered mouse models (GEMMs) and 
patient-derived xenografts (PDXs) for preclinical testing have gone far to address many 
of these failings.  
 While they are far from perfect, mouse models provide valuable information that 
can influence the design of human trials. GEMMs are designed to closely mirror human 
tumor development, with relevant mutations expressed in corresponding cell types. 
Importantly, they provide an avenue to study early stages of disease, which is not 
possible in cell lines or even primary tumor samples. These studies provide insights into 
how disease develops and factors that influence progression. Pre-malignant stages in 
tumor models have been used to identify potential drivers in SHH-driven MB77, 
pancreatic cancer298,299, and colorectal cancer298,300. They are particularly useful for 
elucidating microenvironment- tumor cell interactions and identifying potential 
sensitivities that can be exploited for therapy. Patient derived xenografts (PDX) provide 
some unique advantages as well. They capable of modeling the diversity and 
heterogeneity that occurs in human tumors, which is useful for studying tumor biology 
and response to therapy. Importantly, direct transplantation of tumors into orthotopic 
sites has been shown to maintain the features and expression profiles of the original 
tumors during propagation301 237. And while they do not have the advantage of growing in 
native environment, they are derived directly from human tumors and orthotopic models 
mimic a normal microenvironment to some degree. Initial studies that progressively test 
standard of care therapeutics in more complex GEMMs and now in PDX models suggest 
that there is significantly enhanced translational accuracy of these models301,302. It 
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remains to be seen how well predictions of these models for novel therapies translate to 
clinical efficacy.  
Additionally, these models allow for evaluation of PD/PK parameters to assist 
with study design for human trials. While drugs may be metabolized differently in mice 
and humans, they provide in an avenue to start to evaluate bioavailability of the drug in 
the target tissue, which is difficult to assess in human tumors303. Studies in preclinical 
models of MB and colorectal cancer demonstrated how small changes in exposure of 
tissues to GDC-0449 corresponded to a big change in anti-tumoral activity304, which is 
critical for determining dosing for trials. In vivo models are also extremely helpful for 
identifying potential organ toxicities and drug interactions that would not be addressed in 
cell line based testing. Interestingly, recent studies in mice have shown that dose timing 
has an effect on development of resistance. Studies have using intermittent dosing of 
vemurafenib  not only prolonged response compared to constant drug exposure, but 
actually saw some tumor regression when drug was withdrawn due to acquired drug-
dependence305. These types of studies are critical for preclinical development of drugs 
and designing optimal dosing schedules.  
What is needed now are ways to increase the predictive power of our current 
models and/or development of more representative models. With our increased 
understanding of cancer genome, we are much better equipped to develop genetic 
models that are driven by relevant genetics and more closely phenocopy human 
disease.  Beyond that, there are two main areas in which we can improve the preclinical 
power: model selection and modifications to study design.  
Model selection will be a key factor for improving outcomes. Prior to use in a 
preclinical setting, models should be rigorously tested to verify that they recapitulate the 
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human disease in terms of histology, gene expression, display consistent growth 
phenotypes, and very critically, should be verified that they mimic response to standard 
of care therapies297,302. Another major factor is asking the right type of question in the 
right model.  PDX models are suitable for testing therapies that specifically impact tumor 
cell intrinsic properties and have been useful for identifying mechanisms of resistance306-
308
 while GEMMs are particularly useful for testing drugs that target non-tumor cells or 
influence immune system responses (microenvironmental factors). The importance of 
model selection is highlighted in a study by Oliver et al. Using a well characterized GEM 
model of pancreatic ductal adenocarcinoma, researchers identified poor drug perfusion 
as a mechanism of gemcitabine resistance in pancreatic tumors and further that 
depleting stroma using a SMO antagonist enhances drug delivery. In contrast, 
subcutaneous human xenografts were responsive to gemcitabine and were well 
perfused309. In this case, the GEM  models more accurately represent the response seen 
in humans to gemcitabine and studies performed in PDX models were misleading.  
Changes in study design will be another major way of increasing the predictive 
power of mouse studies. For preclinical studies, factors in study design such as splitting 
litters, balancing for gender across groups, and statistical modeling to determine animal 
numbers should be done routinely. Guidelines such as these (mirroring those used in 
clinical trials) have been suggested to make preclinical studies more uniform and 
interpretable310,311. Additionally, it may be helpful to track genes and closely monitor 
disease phenotypes such as survival time; in models that harbor multiple copies of a 
gene, they can be inherited unevenly leading to changes in disease phenotype over time 
and potentially mask drug response296. It will also be essential to test therapeutics in 
multiple models to demonstrate the robustness of response. Defining appropriate 
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readouts that translate to clinical endpoints will be important as well. Overall survival is 
an ideal preclinical endpoint, but only really appropriate for GEMMs. For PDX tumors, 
especially subcutaneous models, recurrence or progression may be a better endpoint to 
consider.297  
In terms of human trials, it will be essential to test drugs in the correct patient 
cohort in order to see efficacy. Identification of relevant patient populations will come 
both from analysis of patient derived expression profiles and subtyping based on mouse 
models. There has also been recent advent of “co-clinical trials” in which mouse studies 
are run in parallel with human trials. Since the mouse trials move faster, they can 
provide a sense of how well the therapies will work, pinpoint potential mechanisms of 
resistance, and identify biomarkers that can influence parameters in the ongoing and 
future trials312. A  co-clinical trial in KRas mutant lung cancer was run to determine if 
MEK inhibitor increases efficacy of docetaxel, a current standard of care therapy. In the 
mouse model, researchers found that cancers with mutations in KRAS and Lkb1 are 
resistant to this combination therapy, which can now be validated in human samples in 
the current trial.313. This study highlights the strengths of this parallel approach. 
Integration of improvements in study design and continued development and selection of 
appropriate mouse models will continue to increase the predictive power of preclinical 
models.  
4.2 Studying the Cell of Origin 
The studies in Chapter 2 were aimed at identifying a putative cell of origin for 
WNT driven tumors. It is known that WNT signaling is critical for early specification and 
development of the cerebellum, but it is unclear what cells are later responsive to WNT 
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signaling and can ultimately be transformed by it to form MB. Our studies show that 
WNT signaling is mitogenic for cerebellar stem cells, but not GNPs. And critically, the 
differentiation defects that prolonged signaling causes suggest that a cooperating 
mutation may be required for tumors formation. Knowing which cells are capable of 
responding to WNT provides insights into the early stages of transformation and 
identifies potential vulnerabilities that can be targeted for therapy. Identification of the 
cell of origin is therefore of great interest to both researchers and clinicians.   
A major question that is left to address is how to study the cell of origin. It is 
impossible to study early stages of tumor development directly in humans. Examination 
of expression profiles from primary tumor samples can provide a glimpse of what cell 
types may have arisen from. For example, it was long suspected that SHH-driven tumors 
arose from GNPs in the cerebellum due to similarities in expression of lineage-specific 
markers such as Math1 and elevated expression of components of the hedgehog 
signaling pathway, which is a critical regulator of GNP proliferation. And indeed, studies 
in mouse models of this subtype have verified that GNPs can serve as a putative cell of 
origin34,79,115. But comparison of expression profiles and differentiation status is not 
sufficient to determine cell of origin. For example, it has been proposed that basal-like 
breast cancer is derived from basal stem cells due to their similaries in phenotype314. 
Surprisingly, deletion of Brca1 (commonly altered in basal-like tumors) and p53 in 
luminal progenitors induced tumors that resemble human basal-like breast cancer, while 
tumors arising from deletion in basal stem cells did not phenocopy the human disease. 
Investigation into the cell of origin is commonly done using genetically 
engineered mouse models. Advances in mouse genetics in recent years has allowed for 
exquisite lineage restricted and temporally controlled expression of oncogenes or loss of 
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tumor suppressors in an endogenous and developmentally relevant setting.  These 
methods have been used to investigate the cell of origin in numerous cancers including 
basal cell carcinoma, lung, breast, and prostate cancers 315, in addition to study of early 
stages of tumor development and progression. Elegant lineage tracing studies using a 
mosaic labeling strategy to delineate contributions of difference cell populations to 
glioma formation identified oligodendrocyte precursor cells as a putative cell of origin for 
glioma316. Additionally, studies in intestinal and lung cancers have demonstrated that 
introduction of mutations into various cell populations have significantly different effects; 
APC deletion in stem cells causes adenomas, while activation in transit-amplifying cells 
rarely induces benign intestinal tumors317,318 . In NSCLC, KRasG12D causes 
adenocarcinoma in AT2 cells (not in bronchioavleolar stem cells) 319, while mutations of 
Rb1 and p53 in neuroendocrine cells alone causes development of SCLC320 . These 
studies demonstrate the importance of pairing certain mutations and cellular contexts in 
order to model specific subtypes of disease. Since mutations only cause transformation 
in certain cells, understanding the reasons for their particular sensitivity would be helpful 
in identifying new therapies.  
These approaches have also been used to identify the cell of origin in the context 
of MB as well. Numerous studies have demonstrated that multiple cerebellar progenitor 
cells can form MBs after activation of the Shh pathway34,79,115. Additionally, a recent 
paper by Gilbertson et al identifies BLBP+ brain stem progenitors as a potential cell of 
origin for WNT-driven tumors24. They demonstrated that these tumors closely resemble 
the human WNT-associated disease in terms of tumor location in proximity to the brain 
stem and gene expression.  Importantly, their data are in agreement with ours that WNT 
pathway activation alone is not mitogenic for GNPs of the cerebellum. While this study 
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provides evidence for a cell of origin for WNT tumors, this does not exclude the 
possibility that cells from the cerebellum are another source of tumor-generative cells. 
Their model was compared to a small subset of human tumors (n=6), so may only be 
representative of a small portion of the WNT subtype tumors. Unfortunately, due to the 
deleterious effects of WNT activation in cells outside the cerebellum, we were not able to 
follow the long term fate of cerebellar stem cells to determine if they represent a true cell 
of origin. Additionally, our finding that WNT activation causes self-renewal defects in our 
cells suggests that additional mutations may be required in these cells to support 
extended growth. Studies with more restricted Cre driver expression and coupled with 
introduction of cooperative second hits will be critical for addressing the cell of origin 
question for this subtype. 
4.3 Target identification in WNT tumors 
Whether or not we have identified the right cell of origin for these tumors, there 
are important implications of our studies for development of therapies for WNT tumors. 
We show that WNT signaling is mitogenic for stem cells initially, but more importantly 
that prolonged elevated signaling causes defects in self renewal. Since WNT driven 
tumors do occur, this suggests that in some contexts (cellular and/or genetic), WNT 
signaling can promote tumor formation. Whatever mechanism used to overcome this 
defect to allow for extended proliferation and progeny generation in tumors could 
represent a point of vulnerability for these tumors. Identifying the second hit that these 
cells depend on for growth and survival will therefore be critical for developing new 
therapies. To do this, analysis of human genomics coupled with mouse studies such as 
ours will be needed. In the case of the Gilbertson model, WNT activation cooperates 
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with p53 inhibition to cause accelerated tumor formation. This could be representative of 
the ~10% of human WNT-driven cases that display altered p53 expression.  The 
remaining majority of cases are still unrepresented and need to be evaluated. Using our 
findings, closer analysis of human MB datasets with an eye towards genes that could 
influence stem cell fate determination may provide critical insights into cooperating 
mutations and development of a novel WNT-driven model that represents other subsets 
of WNT patients. The most common genetic alteration that occurs in this subgroup of 
tumors is monosomy 6, so genes that are expressed on this chromosome (e.g. p53) may 
represent cooperating second hits. Alternatively, a recent study has identified unique 
chromosomal modifiers that are mutated in some WNT driven MB tumors, including 
SMARCA4 (ATPase) and CREBBP (histone acetyltransferase) which could represent 
novel targets321.  
4.4 Mitotic Inhibitors as targeted therapy 
 Our studies in Chapter 3 highlighted the efficacy of targeting Survivin, a 
key regulator of mitosis, for treatment of MB. Based on the idea that tumor cells 
proliferate more rapidly than normal cells, proteins that regulate the cell cycle are 
generally considered attractive candidates for selectively inhibiting tumor growth and 
sparing normal, less proliferative tissues. A number of chemotherapeutic agents, such 
as microtubule targeting agents paclitaxel and vincristine, have shown significant 
efficacy in patients322, although they do display some myeloid and neuronal toxicities due 
to altered microtubule dynamics in non-dividing cells323-325 and resistance eventually 
develops322. Prompted by these successes and a desire to limit inhibition to actively 
dividing cells, focus has shifted to inhibiting mitotic regulators. Mitosis is considered to 
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be the most fragile part of the cycle due to the complex changes that have to be strictly 
orchestrated through this phase, and perturbations lead to extended mitotic arrest 
through activation of the spindle assembly checkpoint and eventual signals for mitotic 
cell death326,327. Antagonists targeting mitotic entry (e.g cyclin dependent kinases, 
CDK1/2), mitotic kinases (e.g. aurora kinases, polo-like kinases) and kinesin spindle 
proteins (e.g. KPS, Eg5, CENP) have shown promise in vitro and in xenograft models 
327-333
 and numerous clinical trials have been initiated using these compounds327,331. 
Consistent with this, our data suggest that targeting mitosis through survivin inhibition is 
an effective way to treat MB and clinical trials with survivin antagonists have shown 
modest responses in other solid tumors218,222,225,248. Together, targeting mitosis appears 
to be a promising avenue for therapy. 
Despite the apparent efficacy of these inhibitors in preclinical tests, there is 
debate as to whether targeting mitosis is the right strategy for cancer therapy. In general, 
preclinical efficacy has not translated to clinical success; a very low response rate has 
been seen across clinical trials in solid tumors for antagonists of the aurora and polo-like 
kinases, or mitotic kinesins as single agents328,331. This could be due in part to the limited 
expression and function of these targeted molecules in G2/M phase178,334. Therapies that 
rely on inhibition of these proteins will only inhibit the small fraction of cells that are in 
G2/M phase at the time of treatment and spare the rest. While this is desirable to limit 
toxicity, there is evidence from radiological studies that doubling time for human solid 
tumors in vivo can be well over 100 days, in contrast to 3-6 day range suggested by 
xenografted tumors or in vitro331,335. It is likely therefore that very few cells would be 
affected by antagonists unless they were given frequently and for long periods of time. 
Additionally, a recent study with Eg5 has demonstrated that point mutations in the 
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protein can cause drug resistance to develop336. And in general, resistance to anti-
mitotics can occur through a mechanism call “mitotic slippage”, in which arrested cells 
escape the arrest without completing mitosis and either die or instead form viable 
multiploid cells which can display increased chromosome instability that can affect 
further promote malignant growth327,337,338. Lastly, if there is a population of quiescent 
cells within the tumors, they will not be affected by mitotic targeted therapies and could 
contribute to resistance and recurrence. A number of studies have identified cell 
populations within leukemias, so called tumor-propagating (TPCs) or cancer stem cells, 
which are quiescent339,340 and may therefore prove to be refractory to mitotic-targeted 
therapies 
 In contrast to the leukemias, Dr. Rich and others have identified TPCs (marked 
by CD133+ expression) in human brain tumors that are not quiescent341,342 and would 
therefore be less likely to be a barrier to mitotic therapy. Consistent with this, previous 
studies in mouse models of Shh-driven MB have identified a TPC population 
characterized by CD15 expression that are a highly proliferative343,344. Studies from our 
lab (and others) have shown that inhibitors of Aurora and Polo-like kinases inhibit the 
proliferation of these cells236 and are effective at impairing tumor growth in vivo236,345. 
Importantly, we have seen similar results with our Survivin antagonists in our studies 
outlined in Chapter 3; Survivin antagonists effectively inhibit both bulk tumor growth and 
proliferation of CD15+ and CD15- cells in vitro (data not shown). So targeting mitotic 
regulators such as Survivin may still be an effective treatment strategy for MB. 
 Importantly, Survivin antagonists are not just mitotic inhibitors. Survivin 
expression has also been noted in tumors with low mitotic index346, suggesting that 
expression is not merely a consequence of increased proliferation. And while Survivin 
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plays an important role in mitotic progression, survivin is not necessarily unilaterally 
involved in mitosis. In tumors, survivin is commonly expressed throughout interphase, as 
well as S phase347, while its expression is restricted predominately to G2/M phase in 
most untransformed cells. This aberrant expression may reflect alternative functions for 
Survivin beyond its mitotic role in tumors. Critically, Survivin may represent a particular 
point of vulnerability for tumors. It is at the intersection of numerous pathways that 
facilitate malignant growth, influencing proliferation, survival, angiogenesis, and 
mediating therapy resistance. Combined with the low expression in normal tissues, 
these functions of survivin make it an ideal target for MB treatment.  
4.5 Survivin antagonists to overcome resistance 
Focus in recent years in cancer treatment is the concept of personalized 
medicine and the development of targeted therapies. These drugs are based on specific 
alterations that cancers depend on for growth and (ideally) are selective for tumor cells, 
so are significantly safer to patients than traditional chemotherapy. One of the earliest 
success stories in development of targeted therapies is Gleevec (Imatinib). Gleevec 
inhibits Bcr-Abl348, an oncogenic fusion protein that is expressed in the majority of 
patients with chronic myelogenous leukemia (CML)349, and its phenomenal success 
transformed CML into a treatable disease350,351. Following this success, there has been a 
flurry of targeted therapies in clinical trials for numerous cancers, including BRAF and 
MEK inhibitors for melanoma86, anti-Her2 antibodies or inhibitors in breast cancer87, and 
EGFR and ALK inhibitors in NSCLC352,353. In MB, a number of small molecule 
antagonists of Smoothened (a regulator of the SHH pathway) have been tested in the 
Shh-subtype of medulloblastoma (LDE-225, GDC-0449, IP1-926) and have shown 
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efficacy in mouse models and are in trials90,92-94. One of the major drawbacks of targeted 
therapy however has been the rapid development of resistance95. Investigations in MB, 
breast cancer, melanoma, and others have identified some common mechanisms of 
resistance. Mutations in the drug target itself or in downstream effectors of the targeted 
pathway occur frequently86,87,352,354,355. Additionally, activation of alternative pathways 
that circumvent the dependence on the original target have been identified86,87,352,354. 
PI3K pathway activation is one such evasive mechanism that occurs commonly across 
cancer types87,95,356. What is needed now is either a way to prevent resistance or a ways 
to treat resistant tumors.. 
Survivin antagonists may represent an important tool for treatment of resistant 
tumors. Studies in lung cancer have already demonstrated the utility of targeting survivin 
(by siRNA or YM155 treatment) for reversing Erlotinib resistance254. So treating with a 
combination of targeted agents, including survivin antagonists, may be helpful in 
preventing the development of resistance. As mentioned above, a common mechanism 
of resistance is activation of the PI3K pathway. Survivin is a downstream target of this 
pathway ( through Akt)357,358, so it is possible that inhibition of survivin could prevent 
some of the survival advantages incurred by PI3K pathway activity. It is well understood 
that Survivin is at the intersection of numerous pathways associated with malignant 
growth, so inhibition may disrupt other signals that mediate resistance as well. 
Our in vitro data with combination treatment of LDE-255 and Survivin antagonists 
suggests that they can cooperate to inhibit tumor proliferation. Whether this combination 
prevents the development of tumor resistance in vivo or whether tumors that have 
become LDE resistant can be inhibited by survivin antagonists is an interesting question 
that remains to be studied. The optimal timing of treatments will be important to address 
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as well. Advantages of up-front combination of agents vs sequential treatment should be 
investigated. And as some studies have suggested that cycles of recovery should be 
included in treatment regimens to decrease the likelihood of resistance developing, 
proper combination treatment in this context will be interesting to explore.   
4.6 The blood-tumor barrier and delivery of CNS therapeutics 
Our data suggest that survivin antagonists robustly inhibit the growth of MB in the 
periphery, while they are incapable of inhibiting intracranial tumor growth. One reason 
for this may be poor blood brain barrier penetration of our antagonist.  It is well 
established that in healthy brain, the BBB is critical for excluding the majority of 
molecules from entry into the brain, including (and especially) potential 
therapeutics359,360. Similarly, there is mounting evidence that that there are alterations in 
the BBB as consequence of brain tumor growth and that  the compromised barrier, so 
called blood-tumor barrier  (BTB),  is more permissive than the BBB238. Patients with 
high grade brain tumors display contrast enhancement in MR images and CT scans361-
363
 as well as an increased infiltration of plasma proteins364. Additionally, gliomas display  
physical alterations in capillary endothelial cells365 that form the barrier and 
downregulation of tight junction proteins (e.g. claudins, Occludin, AQP4), causing 
junction disruption and increased edema366 362,365,367,368.  Further,  studies demonstrate 
that p-Glycoprotiens ( the major drug efflux transporters in the BTB) have lower 
expression in metastastic  BTB as well369, although reports are less clear in primary 
glioma models370,371. These data together suggest that the BTB is less intact than the 
healthy BBB and therefore may not pose as strong an issue for drug delivery.  
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While there is definitive evidence for an altered BTB in context of brain tumors, it 
is unclear whether the increased leakiness is sufficient to enhance drug delivery to 
tumors. There is evidence that increased contrast enhancement does not necessarily 
correlate with increased drug delivery372. Even with impaired barrier integrity, it is unlikely 
drugs can penetrate sufficiently to inhibit the entire tumor. Models of primary or 
metastatic brain tumors show heterogeneous permeability of the barrier around the 
tumor bulk363,373, with highest permeability around the tumor core and minimal change 
around the growing, more infiltrative edges374. This translates to variation in drug 
distribution to tumor areas, such that it is unlikely that drugs can achieve high enough 
concentrations to kill all tumor cells375.  Significantly, a study by Salphati et al. 
demonstrated that a PI3K inhibitor is incapable of inhibiting growth of infiltrative gliomas, 
while a brain-permeant version inhibits growth of both infiltrative and non-infiltrative 
tumors376. These studies demonstrated both that BTB permeability varies between tumor 
types (infiltrative vs growth as a mass) and that drugs designed to cross the barrier are 
more effective than those that don’t, even in the context of a compromised BTB.  
As further evidence that the BTB remains an impediment for treatment, 
interference with BTB function enhances efficacy of drugs against tumor growth. 
Osmotic barrier disruption enhanced distribution and efficacy of antibodies and 
doxorubicin-immunoconjugates against glioma xenografts, 377,378, suggesting that there 
was still BTB-mediated exclusion of these therapeutics.  Similarly, pharmacological 
inhibition or knockout of drug efflux transporters (of which many drugs are substrates238) 
augments drug delivery and efficacy against brain tumors379 380. Finally, drug levels in 
tumors in peripheral tissues are significantly higher than found in brain tumors375,381. This 
translates to an obvious difference in drug efficacy in gliomas grown in the periphery 
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compared to brain that suggests the barrier is still an obstacle for treatment of CNS 
tumors382,383. Consistent with this, our data suggest that there is a relatively intact blood-
tumor barrier that prevents our small molecules from crossing at sufficient levels into the 
brain (see Figures 30-32 and Table 3).  Importantly, this is in the context of both 
endogenous tumors and in a transplantation setting, where there is already the question 
of compromised barrier due to the physical disruption involved in implanting the cells.  
Beyond initial entry into brain, there are other factors influencing drug efficacy 
that have to be addressed for treatment. The extent to which the tumor cells themselves 
have functional multidrug transporters is a critical issue. Some studies suggest that 
gliomas and glioma-associated ECs from new tumor vasculature express p-glycoprotien 
at similar levels as other regions of brain371,384.  And as mentioned above, alteration in p-
glycoprotein expression does lead to enhanced drug accumulation in tumors. So even if 
drugs get through a compromised barrier, they may still be excluded from tumor cells by 
transporters. Interstitial fluid pressure in tumors can also have a substantial impact on 
drug penetration through the tumor even if they get through the barrier385,386. These 
issues should be taken into consideration as we move forward with development of new 
treatments for brain tumors. 
The future of treatment of tumors in the CNS, whether primary or metastatic, will 
be highly dependent on enhancing delivery to the tumors, both through the BTB and 
increasing uptake into tumor cells. In the discussion of Chapter 3, we highlight some 
potential methods of circumventing the barrier as a way to increase drug delivery to 
tumors; by transient disruption of the barrier (e.g. osmotic perturbations, FUS, inhibition 
of MDTs), bypassing  it completely (e.g. CED or intrathecal delivery ), or facilitated entry 
such as with nanoparticle mediated delivery.  Methods to transiently disrupt or impair 
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barrier function will be necessary in order for promising candidates, such as Survivin 
antagonists, to be translated to the clinic for treatment of MB. 
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5. Materials and Methods 
5.1 Methods for Chapter 2 
5.1.1 Mice 
Catnblox(ex3)/+ mice117, Apclox/lox mice387 and Catnblox(ex2-6)71 mice have been described 
previously. hGFAP-Cre118 mice and hGFAP-green fluorescent protein (hGFAP-GFP)116 
mice were from Jackson Laboratories, and Math1-Cre mice79,115 were provided by David 
Rowitch at UCSF. All mice were maintained in the Cancer Center Isolation Facility at 
Duke University. All experiments were performed in accordance with national guidelines 
and regulations, and with the approval of the Duke University Animal Care and Use 
Committee. 
5.1.2 Immunostaining 
Tissue was harvested from embryos or neonates, fixed in 4% paraformaldehyde (PFA), 
equilibrated in 25% sucrose at 4°C and frozen in Ti ssue-Tek OCT (Sakura Finetek, 
Torrance, CA, USA). For bromodeoxyuridine (BrdU) staining, pregnant females were 
injected with 100 mg/kg BrdU prior to embryo harvest. Cryosections (12 m) were 
blocked with 10% goat serum in 0.1% Triton X-100 at room temperature and primary 
antibodies were applied overnight at 4°C. Antibodie s included rabbit anti-Ki67 (Abcam, 
Cambridge, MA, USA; 1:100) or mouse anti- Ki67 (BD Biosciences, San Jose, CA, USA; 
1:100), rabbit anti-Sox1 (gift of Larysa Pevny, University of North Carolina, Chapel Hill; 
1:1500), rabbit anti-β-catenin (Abcam; 1:2000), rabbit anti-calbindin (EpitMics, 
Burlingame, CA, USA; 1:250), rabbit anti-Pax2 (Covance, Princeton, NJ, USA; 1:250), 
rabbit anti-Pax6 (Covance; 1:300), mouse anti-S100β (Sigma; 1:500), rabbit anti-Map2 
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(Chemicon/Millipore, Temecula, CA, USA; 1:1000), rabbit anti-BLBP (Chemicon; 1:500), 
mouse anti-GFAP [cocktail of monoclonal antibodies (clones 4A11, 1B4, 2E1), BD 
Pharmingen; 1:100] and rat anti-BrdU (Abcam; 1:100). Secondary antibodies included 
goat anti-mouse Alexa Fluor 594 and goat anti-rabbit Alexa Fluor 488 (Invitrogen, 
Carlsbad, CA, USA) used at 1:200. Noggin, Bmp2 and Bmp7 proteins were purchased 
from Peprotech (Rocky Hill, NJ, USA) and used at 200 ng/ml. p21shRNA retroviral 
plasmid (Fasano et al., 2007) was a gift from Sally Temple at the Neural Stem Cell 
Institute, Rensselaer, NY, USA. Cre retrovirus was a gift from Tannishtha Reya 
(University of California, San Diego). 
5.1.3 Cell isolation and flow cytometry 
Cells were isolated from embryonic (E14.5) or neonatal (P0) cerebellum as described78. 
Briefly, tissue was digested in a solution containing 10 units/ml papain (Worthington) and 
250 U/ml DNase, and triturated to obtain a single-cell suspension.To isolate prominin 1+ 
lineage-negative (Prom1+ Lin–) cells from wildtype (WT) or mutant mice, cells were 
suspended in FACS buffer (Dulbecco’s PBS with 5% FCS). Cells were stained for 1 hour 
with phycoerythrin (PE)-conjugated rat anti-prominin 1 antibody (clone 13A4, 
eBioscience, San Diego, CA, USA; 1:200) and with antibodies specific for lineage 
markers [polysialylated neuronal cell adhesion molecule (PSA-NCAM), 
Chemicon/Millipore, 1:200; O4, Chemicon/Millipore, 1:100; TAPA-1 (CD81), 
eBioscience, 1:250]. After staining with FITC-conjugated secondary antibodies, cells 
were washed and analyzed or sorted using a FACS-Vantage SE flow cytometer (BD 
Biosciences). PE conjugated rat IgG was used as a negative control. 
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5.1.4 In vitro analysis of proliferation, differentiation and neurosphere 
formation 
5.1.4.1 Ki67 Staining  
To analyze the effects of β-catenin on proliferation, cells were cultured in Neurobasal 
medium with B27 supplement (NB-B27, Invitrogen) on poly- D-lysine (PDL)-coated 
chamber slides (5 x 104 cells/well). β-catenin-IRES-YFP or control YFP viruses were 
added and cells incubated for 48 hours before staining with anti-Ki67.  
5.1.4.2 Thymidine incorporation 
To assay incorporation of tritiated thymidine, cells were cultured in PDL-coated 96-well 
plates at 2 x 105 cells/well. β-catenin-IRES-GFP or control GFP viruses were added and 
cells incubated for 48 hours before being pulsed with methyl- [3H]thymidine (GE 
Healthcare, Piscataway, NJ, USA). After 16 hours, cells were harvested using a Mach 
IIIM manual harvester 96 (Tomtec, Hamden, CT, USA), and incorporated radioactivity 
was quantitated using a Wallac MicroB microplate scintillation counter (Perkin Elmer, 
Waltham, MA, USA). 
5.1.4.3 Differentiation 
To analyze the differentiation potential of WT or mutant NSCs, Prom1+ Lin– cells were 
plated on PDL-coated coverslips in NB-B27 plus 1% FBS, and cultured for 3 days before 
fixation with 4% PFA, permeabilization with 0.1% Triton X-100, and blocking with 10% 
goat serum. Cells were stained with anti-Map2 and anti-S100β. 
5.1.4.4 Neurosphere formation 
To measure neurosphere formation, Prom1+ Lin– cells were cultured at 2000 cells/ml in 
uncoated wells containing Neurocult with proliferation supplement (Stem Cell 
Technologies, Vancouver, BC, Canada) plus 25 ng/ml bFGF (Invitrogen) and 25 ng/ml 
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EGF (Peprotech). Cells were cultured for 7 days and photographed under bright-field 
microscopy. To examine self-renewal, spheres were dissociated in 0.05% trypsin/EDTA 
(Invitrogen) and replated at 2000 cells/ml. 
5.1.5 Real-time RT-PCR 
mRNA was isolated using the RNAqueous kit (Ambion, Austin, TX, USA) and treated 
with DNA-free DNase (Ambion). cDNA was synthesized using oligo(dT) and Superscript 
II reverse transcriptase (Invitrogen). Real-time RT-QPCR reactions were performed in 
triplicate using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) and the Bio-
Rad iQ5 Multicolor Real-Time PCR Detection System. Gene expression was normalized 
to actin (Actb), and expression of each gene was compared between WT and G-Cat 
mice from the same litter. Primer sequences are listed in Table 4. 
5.1.6 Statistical analysis 
Statistical significance was determined by Student’s t-tests and, in the case of gene 
expression, by performing a two-factor ANOVA to identify genotype-by-gene interaction 
and post-hoc two-tailed t-tests (for P-value). 
Table 4:Primers for qPCR 
Gene Primer Sequence 
Actin Forward TATTGGCAACGAGCGGTTCC 
Reverse GGCATAGAGGTCTTTACGGATGTC 
Bmi1 Forward CAACTTCTCCTCGGTCTTCA 
Reverse AGCTGATGCTGCCAATGGCTCCA 
Hes1 Forward GCCAATTTGCCTTTCTCATC 
Reverse ACATGGAGTCCGAAGTGAGC 
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Hes5 Forward CCTCACCTCAAGGTCCACAT 
Reverse TGTTCTCCCACATGACCAAG 
c-Myc Forward CTCTCCTTCCTCGGACTCG 
Reverse GGTTTGCCTCTTCTCCACAG 
Bmp2 Forward TGGACGTGCCCCCTAGTGCT 
Reverse GGATGCCGCGGCGAACTTCT 
Bmp7 Forward GCGCAGCCAGAATCGCTCCA 
Reverse ATGGCGTGGTTGGTGGCGTT 
p21 Forward CTGTCTTGCACTCTGGTGTCTGAG 
Reverse TTTTCTCTTGCAGAAGACCAATCTG 
 
5.2 Methods for Chapter 3  
5.2.1 Mice 
Survivinfl/fl 160, Ptcfl/fl 388, Math1-Cre-ER28, Math1Cre and Math1CreER;ptcfl/fl 115 
(MERP) mice have been described previously. P4 MERP pups were gavaged with 
0.8g/40µl of tamoxifen (T-5648, Sigma, St. Louis, MO) in corn oil to generate tumors. 
Tumors from Ptch+/- and MERP mice were used for experiments and are referred to as 
Ptch mutant tumors in the text. To allow for deletion of survivin in tumor cells, Survivinfl/fl 
mice were crossed with Ptch+/- mice to generate the Survivin fl/fl; Ptch+/- (SP) line.  This 
line was further crossed to Math1-Cre-ER mice to generate the Survivinfl/fl; Math1-Cre-
ER; Ptc+/- (SMEP) mice. To assess the effects of survivin loss on tumor formation, 
Math1Cre mice were crossed with Survivinfl/fl and Ptcfl/fl mice to generate the Math1Cre; 
Survivinfl/fl; Ptcfl/fl (MCSP) line. MP tumor mice were described previously80. CD-1 Nu/Nu 
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mice and Fox Chase SCID/Beige (CB17.Cg-PrkdcscidLystbg-J/Crl) mice were obtained 
from Charles River Laboratories (Wilmington, MA). P7 wild type C57BL/6 pups were 
obtained from the SBMRI Animal Facility. All mice were maintained in the Animal 
Facility, and experiments were performed in accordance with national guidelines and 
regulations, and with the approval of the SBMRI Institutional Animal Care and Use 
Committee.  
5.2.2 Cell isolation and in vitro culture 
GNPs were isolated from P7 cerebellum and tumors from adult cerebellum as 
previously described78,115. Briefly, tissue was digested in a solution containing 10 U/ml 
papain (Worthington Biochemical Corporation, Lakewood, NJ) and 250 U/ml DNase 
(Sigma), and triturated to obtain a single-cell suspension. Cells were spun through a 35-
65% Percoll gradient (GE Healthcare Uppsala, Sweden) to purify GNPs and tumor cells. 
Cells were cultured in NB/NS-21 media (Neurobasal media, 1 mM sodium pyruvate, 2 
mM L-glut, penicillin/streptomycin and NS-21 supplement, plus 1% FBS (Invitrogen 
Grand Island, NY)) on growth factor-reduced (GFR) matrigel-coated plates (1:50 in 
NB/NS-21, BD Biosciences, San Diego, CA). 
 
5.2.3 Real-Time PCR 
For analysis of survivin expression, mRNA was isolated from cells and tissues 
using an RNAeasy Plus Mini kit (QIAGEN Inc, Valencia, CA). One-step qRT-QPCR 
reactions were performed in triplicate using QuantiTech RT mix (QIAGEN) on the Bio-
Rad C1000 Thermocycler and CFX96 system (Bio-Rad Laboratories, Hercules, CA). 
Duplicate reactions were prepared without reverse transcriptase to confirm the absence 
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of genomic DNA contamination.  Relative gene expression was calculated using the 
∆∆CT method and normalized to Actin. 95% confidence intervals for each sample were 
calculated using the sum of the squares method. To evaluate the efficiency of survivin 
deletion by Cre infection, SP tumor cells were isolated, infected with Cre-IRES-GFP or 
GFP retroviruses for 48hrs, sorted for GFP expression, and analyzed as outlined above. 
5.2.4 Immunohistochemistry 
5.2.4.1 Survivin staining 
For staining of paraffin-embedded tissue, animals were perfused with PBS 
followed by 4% paraformaldehyde (PFA, Affymetrix, cat# 19943). Cerebella and tumors 
were removed, fixed in 4% PFA overnight and delivered to the SBMRI Histology Shared 
Resource for embedding, antigen retrieval, and staining. Sections were stained either 
with anti-Survivin antibodies (Cell Signaling Technology Cat#2808S, Danvers, MA) alone 
or anti-Survivin antibodies pre-incubated with Survivin blocking peptides (Cell Signaling 
Technology Cat #1037). 
5.2.4.2 Frozen section staining 
For staining of frozen tissue, animals were perfused with PBS followed by 4% 
paraformaldehyde (PFA)(Affymetrix). Cerebella were removed, fixed in 4% PFA 
overnight, cryoprotected in 30% sucrose, frozen in TissueTek-OCT (Sakura Finetek, 
Torrance, CA), and cut into 10–12 mm sagittal sections. Sections were rehydrated in 
PBS (Invitrogen) for. Slides were then blocked and permeabilized for 1 hr with PBS 
containing 0.1% Triton X-100 (Aqua Solutions Deer Park, TX) and 1% normal goat 
serum (Jackson ImmunoResearch Laboratories, Inc. West Grove, PA) and stained 
overnight with anti-Ki67 (1:100 BD Pharmingen, San Jose,CA) or CC3 (1:200 Cell 
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Signaling Technology, Danvers, MA antibodies) at 40C. and incubated with alexa fluor 
rabIgG-594 secondary antibodies(1:200, Invitrogen Molecular probes Eugene, OR) for 2 
hr at room temperature. Sections were counterstained with DAPI and mounted with 
Fluoromount-G (Southern Biotech, Birmingham, AL) before being visualized using a 
Zeiss LSM-700 confocal microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY). 
5.2.5 Cell Lysis and Western-blotting 
To evaluate Survivin expression, tumor cells, GNPs and adult cerebellum were 
lysed in RIPA buffer (Millipore, Billerica, MA). Protein was quantitated using the Bio-Rad 
protein assay. Equal amounts of protein were separated by SDS-PAGE, blocked with 
5% BSA (Sigma) in Tris-buffered saline with 0.1% Tween-20 (TBST), and stained with 
anti-Survivin or GAPDH antibodies overnight (1:1000, Cell Signaling Technology Cat# 
2808S, 5174) followed by anti-rabbit HRP-conjugated secondary antibody (1:2000 Cell 
Signaling technology, Cat# 7074S). Proteins were visualized by incubating with Pierce 
ECL plus (Thermo Fisher Scientific, Rockford, IL). To evaluate Survivin expression after 
YM155 treatment, tumor cells were plated on 6-well plates (6-8M cells/well) and treated 
with YM155 or DMSO (Fisher Scientific Inc. San Diego, CA) at 1 µM for 24hrs and 
processed as described above.  
 
5.2.6 Analysis of proliferation, cell cycle and apoptosis  
To analyze the effects of Survivin loss, cells were isolated from SP tumors and 
infected with Cre-IRES-GFP or GFP retroviruses (MSCV, 1:5 in media). To assess the 
effects of pharmacological inhibition of Survivin, Ptch mutant tumor cells were treated 
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with YM155 (Selleck Chemicals), S12230, LLP3231, or DMSO (Fisher Scientific) at the 
indicated concentrations.  
5.2.6.1 Ki67 staining:  
Cells were plated on GFR matrigel-coated chamber slides at 0.2M cells/well and treated 
with DMSO or antagonists for 24hrs. Cells were fixed in 4% PFA, permeabilized with 
0.1% Triton X-100 in PBS (Aqua Solutions Deer Park, TX) and blocked with 10% goat 
serum (Jackson ImmunoResearch Laboratories, Inc. West Grove, PA) before staining 
with anti-Ki67 (BD Biosciences Cat# 556003) and 4',6-diamidino-2-phenylindole (DAPI, 
Invitrogen). Six representative images from each treatment were collected using the 
Zeiss LSM-700 confocal and Ki67+ percentages calculated using ImageJ software 
(NIH).  
5.2.6.2 Thymidine incorporation 
 Cells were plated (2 x 105 cells/well) in GFR-matrigel coated 96 well plates and 
treated with either virus or antagonists for 48hrs in triplicate wells before being pulsed 
with methyl-[3H]thymidine (GE Healthcare, Piscataway, NJ, USA). After 12-16 hr, cells 
were harvested using a Mach III manual harvester 96 (Tomtec, Hamden, CT, USA), and 
incorporated radioactivity was quantitated using a Wallac MicroB microplate scintillation 
counter (Perkin Elmer, Waltham, MA, USA).  
5.2.6.3 Cell cycle analysis 
 Cells were plated in GFR-matrigel coated 48 well plates at 0.4M cells/well, 
infected with virus or treated with antagonists, and collected at various time points. Cells 
were fixed and stained using the FITC BrdU Flow Kit (BD Biosciences) and 7-
Aminoactinomycin (7-AAD) according to the manufacturer’s instructions. Analysis was 
 107 
performed using a FACSCanto II flow cytometer (BD Biosciences) and FlowJo v.7.6.4 
software (Tree Star, Inc., Ashland, OR). 
5.2.6.4 Apoptosis 
Tumor cells were plated on 24-well plates at 1M cells/well and treated with 
Survivin antagonists or infected with viruses for 36 hr. Cells were collected by incubating 
with papain solution and resuspended in 100 ul of Annexin-binding buffer containing 5µL 
of AnnexinV conjugate (Annexin-FITC or Annexin-567, both Invitrogen) and 1µl 
Propidium iodide (PI, 1.0mg/ml stock, Invitrogen). Cells were analyzed using a 
FACSCanto II and FlowJo v.7.6.4 software.  
5.2.6.5 Live/Dead Assay 
To address toxicity of YM155, GNPs were isolated from WT P7 pups and plated 
at 0.2 x 106 cells/well in 2 96 well plates coated with GFR-matrigel for each experiment. 
One plate was maintained in proliferation media consisting of NB/NS-21 and Sonic 
hedgehog (SHH)-containing supernatant (1:5 in media) and treated with either DMSO or 
various doses of YM155 and S12 with each condition in triplicate wells. After 48hrs, cell 
viability was analyzed using the LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen). Briefly, 
cells were stained with 4µM EthD1 for 40 min and fluorescence emission (645 nM) was 
measured using a TECAN infiniteM200 Microplate reader (Morrisville, NC). The second 
plate was maintained in differentiation media (NB/NS-21 containing 25mM glucose and 
25mM potassium chloride) for 5 days to produce post-mitotic neurons. Cells were then 
treated with DMSO or corresponding doses of YM155 and cell viability was evaluated 
after 48hrs. 
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5.2.7 Radiation and LDE225 treatment 
To measure effects of inhibitors in combination with radiation, tumor cells were 
plated in 96-well plates at a density of 0.2 x 106 cells per well and cultured in the 
presence of DMSO, 50 nM YM155, or 10 ug/ml S12. After 24hrs, cells were subjected to 
0, 0.25, or 0.5 Gy radiation using a Gammacell 40 Exactor (Low-dose cesium 137 
irradiator, Best Theratronics Ltd., Ottawa, Ontario, Canada). Cells were cultured for an 
additional 24 hr, and [methyl-3H]thymidine assays were performed as described above. 
To measure effects of inhibitors in combination with the SHH antagonist NVP-
LDE225 (Selleck Chemicals, S2151), tumor cells were plated in 96 well plates at 0.2 x 
106 cells/well and cultured with increasing doses of LDE225 or a single dose of Survivin 
antagonist (10µg/ml S12, 20nM YM255) alone or in combination with LDE225 as 
indicated. Cells were cultured for 48hrs and [methyl-3H]thymidine assays were 
performed as described above. 
5.2.8 Human tumor isolation, propagation, and classification 
Human MB tissue for patient-derived xenografts was obtained from surgical 
resection of tumors at Duke University Medical Center (Durham, NC), Rady Children’s 
Hospital (San Diego, CA) or Texas Children’s Cancer Center (Houston, TX). All 
procedures using human tissue were approved by the Institutional Review Boards of the 
respective institutions. Upon retrieval, the tissue was mechanically dissociated into a 
single-cell suspension, then immediately injected into the cerebella of NSG mice. When 
mice showed signs of MB, tumors were again dissociated into single-cell suspensions 
and re-transplanted back into the cerebella of naïve hosts to establish a propagated line 
for each patient-derived xenograft. Molecular classification of human tumors was 
previously described145,236,237  
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5.2.9 Intracranial transplantation 
SCID-beige mice (6–8 weeks old) were anesthetized with Avertin (0.015mg/kg, 
SBMRI) and placed in a stereotaxic apparatus (Kopf, Tujunga, CA). After exposing the 
skull with a scalpel, a 1 mm diameter hole was drilled in the skull over the cerebellum 
using an 18G needle. A cell suspension (1 × 106 cells in 5-µl NB/NS-21) was slowly 
injected into the cerebellum at a depth of 1.5-2mm, using a 5-µl Hamilton Syringe with 
an unbevelled 24G needle (Hamilton, Reno, NV). After injection, the incision was closed 
using Vetbond. 
5.2.10 In vivo genetic deletion and antagonist treatment 
5.2.10.1 Genetic deletion 
To assess the effects of survivin loss on tumor formation, tumors from SMEP 
mice were infected with Cre-IRES-GFP or GFP expressing retroviruses 24-36hrs and 
GFP+ cells were selected by sorting on a FACSVantage SE Diva or FACSAria flow 
cytometer (BD Biosciences). GFP+ cells were transplanted as outlined above. 
Alternatively, SMEP tumor cells were treated in vitro with 1µM 4-OH tamoxifen for 
24hours, transplanted into NSG hosts, and monitored for survival. To mediate deletion in 
tumors in vivo, mice transplanted with SMEP tumors were treated with either 4.0mg 
tamoxifen in 200µl corn oil or corn oil control by oral gavage 2 weeks after surgery to 
mediate deletion of survivin in tumors.  
5.2.10.2 Antagonist treatment 
For systemic treatments, tumor-bearing NSGs (4 weeks post-transplant) were 
treated with 5mg/kg/day YM155 via microosmotic pump (Alzet, model D2004), 
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15mg/kg/day S12, administered 5x a week by i.p, or vehicle controls and monitored for 
survival.  
5.2.11 Pharmacokinetic Assays 
In vitro BBB-PAMPA and in vivo pharmacokinetic assays were performed in 
collaboration with the Exploratory Pharmacology core at Burnham in Lake Nona, FL. For 
in vitro assay, compounds were sent to core for the assay. Briefly, compounds are 
placed in the top of a microtiter plate that is separated from the bottom compartment by 
an artificial lipid-infused membrane immobilized on a filter. Following the permeation 
period, the concentration of drug in the donor and acceptor compartments is measured 
using UV spectroscopy. For in vivo evaluation of S12 distribution, tumor-bearing NSGs 
were treated with 15mg/kg S12 and plasma, normal brain, and tumor tissue were 
collected at 30 mins or 2 hours post treatment. Samples were flash frozen and sent to 
Lake Nona for LC/MS analysis to measure S12 levels in these tissues.  
5.2.12 Flank tumor implantation and in vivo antagonist treatment 
Cells isolated from tumors were re-suspended 1:1 in NB/NS-21 media and GFR-
matrigel. 100µl of cell suspension (6-7 x 106 cells) was injected subcutaneously into the 
flanks of 5-8 week old CD-1 Nu/Nu mice. Tumor growth was monitored using calipers 
and tumor volume calculated using the formula 0.52*length*width2. Treatment was 
initiated when tumors reached ~100 mm3. For intratumoral injections, tumors were 
injected twice a week with YM155 (20 µM final concentration) or vehicle (20% DMSO in 
saline). For systemic treatments, mice were treated with 10 mg/kg/day YM155 or saline 
by subcutaneous micro-osmotic pump (Alzet, model D2004). Experimental treatments 
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were continued until control tumors reached maximum size of 2000mm3, at which point 
tumors were collected for analysis.  
5.2.13 Statistics 
Unless otherwise indicated, statistics were calculated by ANOVA with post hoc 
student’s t-test. p values of less than 0.05 were considered significant and marked with 
asterisks where appropriate.  
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